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1. Abbreviations
mM Micromolar
3NT 3-Nitrotyrosine
AA-Bis Acrylamide Bisacryamide
ACE Angiotensin-converting enzyme
ACEIs Angiotensin-converting enzyme inhibitors
ACh Acetylcholine
Ang II Angiotensin II
ANOVA Analysis of variance
APS Ammonium persulfate
AT1 Angiotensin II type 1 receptor
AT1A and AT1B Angiotensin II receptor subtypes 1A and 1B
AT1A
-/- mice Angiotensin type 1A receptor-deficient mice
AT1B
-/- mice Angiotensin type 1B receptor-deficient mice
AT2 Angiotensin II type 2 receptor
AT2
-/Y mice Angiotensin type 2 receptor-deficient mice
BSA Bovine serum albumin
Ca Cl2 Calcium Chloride
cGMP Cyclic guanisine-3’, 5’-monophosphate
DMSO Dimethylsulfoxide
DNA Deoxyribonucleic acid
dNTP deoxy-nucleoside triphosphate
DOCA Deoxycortecosterone acetate
DPI Diphenylen-Iodonium
DTT Dithiothreitol
EC50 The concentration that produces half of the maximal response
ECL Enhanced chemiluminescence
EDRF Endothelium derived relaxing factor
EDTA Ethylendiamintetracetate
EGYTA Etylen-Glycol-bis (2-aminoethylether)-N,N,N,N-Tetraacetat
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Emax Maximal efficacy
eNOS Endothelial nitric oxide synthase
eNOS Endothelial nitric oxide synthase
FAD Flavin adenine dinucleotide
GTP Guansinotriphosphate
HEPES N-(2-hydroxyethyl) piperazin –N’-2(ethansulfonic acid)
KCl Ptassium chloride
kDa Kilodalton (as expression for the protein molecular weight)
ko Knockout
L-NAME NG-nitro-L-arginine methyl ester
M Molar (mol/L)
MgCl2 Magnisium chloride
Min Minute
mM Milimolar
NaCl Sodium chloride
 NADPH Nicotinamide  adenine dinucleotide phosphate reduced form
NO Nitric oxide
NOS Nitric oxide synthase
Nox NADPH oxidase
Nox1 NADPH oxidase isoform type 1
Nox2 NADPH oxidase isoform type 2
Nox4 NADPH oxidase isoform type 4
O2-⋅ Superoxide anion
ONOO` Peroxynitrite
PAGE Polyacryliamide gel electrophoresis
PBS Phosphate-buffer saline
PCR Polymerase chain reaction
pD2 -logEC50
PE Phenylephrine
PKC Protein Kinase C
PMSF Phenylmethylsulphonylflouride
RAS Renin-angiotensin system
RLU Relative light unit
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ROS Reactive oxygen species
SDS Sodium dodecyl sulfate
SEM Standard error of the mean
sGC Soluble guanylyl cyclase
SHR Spontaneous hypertensive rats
SLB Special lysis buffer
SOD Superoxide dimutase
Spermine
NONOate
(Z)-1-{N-Ì3-Aminopropyl˝-N-Ì4-(aminopropylammonio)
butyl˝-amino}diazen-1ium-1,2-dioate
TEA Triethanolamine
TEMED N,N,N’,N’-Tetramethyl-1,3-propandiol
Tris 2-Amino—2-hydroxymethyl-1,3-propanediol
TNF-µ Tumour necrosis factor-µ
T-TBS Tris-buffered saline with0.1 % Tween 20
U unit
VSMC Vascular smooth muscle cell
wt Wild type
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2. Introduction
2.1. Angiotensin II (Ang II) Receptors
Ang II is a potent octapeptide of the renin-angiotensin system (RAS) and plays
an important role in structural and functional regulation of cardiovascular system [1,
2]. The physiological actions of Ang II in cardiovascular system are mediated via its
binding to two main receptors, AT1 and AT2. Among the AT1 receptors, two subtypes,
AT1A and AT1B, have been identified in rat and mouse [3]. It is widely accepted that
the AT1 receptors account for majority of cardiovascular effects evoked by Ang II [4,
5]. Stimulation of AT1 receptors leads to cellular growth, hypertrophy, angiogenesis,
vasoconstriction and cardiac remodeling. In contrast, AT2 receptor stimulation results
in antiproliferation including decreased neointimal formation and apoptosis,
antiangiogenesis, vasodilatation, and inhibition of cardiac remodeling [6-9].
Nevertheless, it has been shown that AT2 receptor activation not only counteracts the
Ang II-mediated vasoconstriction, but also actively induces vasodilatation [10-12].
Wherein, range of signaling pathways, including nitric oxide (NO) and bradykinin
production may be involved [12, 13]. An Increasing amount of literature demonstrates
that AT2 receptors-mediated relaxation in a range of isolated arteries including rabbit
renal arterioles [14] and rabbit cerebral arteries [15], which is not only endothelium-
dependent [14] but it is also endothelium-independent [11]. This depends on the
techniques employed, and appears to involve a range of signaling pathways,
including NO-bradykinin production [12] and modulation of K+ channel activity [14]. A
functional interaction has been demonstrated between AT1 and AT2 receptors
concerning vascular tone modulation in vitro [16, 17]. Under basal conditions, an
elevated blood pressure was reported for AT2 receptor knockout mice [18], and mice
overexpressing the AT2 receptor showed a blunted pressure response to chronic Ang
II infusion [19].
The subcellular mechanisms and signaling pathways whereby Ang II mediates
its physiological and pathophysiological vascular effects are complex [20]. Emerging
evidence indicates that production of reactive oxygen species (ROS) and activation
of reduction-oxidation  (redox)-dependent signaling cascades are critically involved in
Ang II-induced pathophysiology [21, 22]. It is well established that AT1 receptor
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activation stimulates non-phagocytic NADPH oxidases (Nox) and generation of ROS
in various vascular cell types, including vascular smooth muscle cells (VSMCs) [23],
endothelial cells [24] and fibroblast [25].
2.1.1. Functional interplay between AT1 receptor subtypes
In rodents, AT1A and AT1B receptors show a sequence homology of 94 % and
are pharmacologically indistinguishable. The AT1A receptor is the major Ang II
receptor subtype expressed in the cardiovascular system of adult mice, suggesting
that this receptor is mainly involved in regulating blood pressure homeostasis.
Indeed, arterial pressure in mice was affected differently by gene targeting of either
the AT1A or AT1B receptor [26-28]. Deletion of the AT1A receptor gene, but not the
AT1B receptor gene leads to a decrease in resting arterial pressure. Blood pressure
increase following Ang II infusion is greatly attenuated but not abolished in
Angiotensin type 1A receptor-deficient mice (AT1A
-/-) [26, 27]. The attenuated pressor
effect of Ang II in AT1A
-/- mice might be due to a deficient vasoconstrictor response,
because the vasoconstriction of isolated arteries is also weakened in AT1A
-/- mice
[29]. In contrast, the elevated pressor effect of Ang II in AT1A receptor-deficient mice
(AT1B
-/-) was not different from that in wt control mice [30].
2.1.2. Interaction between Ang II and NO
Since both Ang II and NO affect vascular tone, fluid volume and remodeling,
they may be protective or deleterious to target organs such as endothelium, vascular
smooth muscle cells (VSMCs) and mesangial cells. Abnormal vascular tone and
vascular remodeling are key features in cardiovascular pathophysiology. Both, NO
and Ang II are important factors in these pathological mechanisms. Imbalance
between Ang II and NO, therefore, leads to development and progression of many
cardiovascular diseases. For example, endothelium-dependent vascular relaxation is
impaired in transgenic mice overexpressing renin or angiotensinogen [31]. Gene
transfer of eNOS effectively restored the vasomotor function in Ang II-infused rabbits
[32]. The vascular response to Ang II is enhanced in eNOS-deficient mice [33].
Furthermore, long-term blockade of NO synthesis with L-NAME caused systemic
arterial hypertension, which could be prevented by AT1 receptor antagonists [33, 34].
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Ang II/NO imbalance often results from loss of NO bioavailability due to endothelial
dysfunction and oxidative stress and/or enhancement of the local tissue actions of
Ang II [35] (Fig.2.1.).
Additionally, NO seems to be a physiological antagonist of Ang II, because it
decreases the level of angiotensin-converting enzyme (ACE) mRNA in endothelium,
downregulates the expression of AT1 receptors in VSMCs and inhibits the production
of endothelin [36-38].
Fig. 2.1. Functional interaction between Ang II and NO: The AT1 and AT2
receptors have contrasting effects (modified after de Gasparo et al.[39]).
2.2. Endothelium and NO
The endothelium plays a key role in maintaining normal vascular function and
structure [40]. Hence, endothelial dysfunction impairs vascular tone, platelet
aggregation and monocyte adhesion, and seems to be associated with an increased
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predisposition to cardiovascular abnormalities. The strategic location of the
endothelium allows discerning changes in hemodynamic forces and blood-borne
signals as well as to respond to these changes by releasing numbers of autocrine
and paracrine substances. Endothelium-derived NO is a physiological mediator of
numerous cellular and organ functions. The formation of NO is catalyzed by NO
synthease (NOS) from L-arginine. Three isoenzymes have been identified, referred
to here as neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS
(eNOS). The cellular effect of NO can be cyclic guanosinmonophosphate (cGMP)-
dependent or cGMP-independent [41]. For the cGMP dependent mechanism, NO
activates soluble guanylyl cyclase (sGC), stimulating production of cGMP. Increased
intracellular cGMP facilitates the extrusion of intracellular calcium and leads to
vascular relaxation. NO has several critical role in the maintenance of vascular
homeostasis. In vasculature, NO not only functions as a vasodilator but also inhibits
VSMCs proliferation and migration, adhesion of leukocytes to the endothelium, and
platelet aggregation [42]. An impairment of the NO signalling pathway, i.e. endothelial
dysfunction, is one of the earliest events in vascular disease [43].
2.3. Role of ROS in vascular pathophysiology
 ROS are a family of highly reactive molecules formed enzymatically in
mammalian cells by reduction of molecular oxygen, producing superoxide anions
(O2-⋅). Under normal conditions, superoxide dismutase (SOD) rapidly reduces O2-⋅ to
hydrogen peroxide (H2O2), followed by its metabolism by other anti-oxidant enzymes,
such as catalase and glutathione peroxidase. Oxidative stress is caused by the
oxidation of macromolecules resulting from the increased formation of ROS and/or
the decrease in the antioxidant reserve. Superoxide anions are critically involved in
the breakdown of NO [44], and the reaction of O2-⋅ with NO leads to production of the
potent oxidant peroxynitrite [45]. Thus, peroxynitrite induces the oxidation of proteins,
DNA and lipids in vascular cells [46].
Investigations during the past decade provide evidence that ROS contribute to
the pathogenesis of numerous cardiovascular diseases, including hypertension,
atherosclerosis, cardiac hypertrophy and heart failure [47]. Of the many factors
implicated in remodeling of vessels in hypertension, Ang II seems to be one of the
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most important. This is supported by in vivo studies examining the relationship
between ROS and hypertension, demonstrating that Ang II-but not noradrenaline-
induced hypertension is associated increased oxidative stress [48]. The significance
of ROS and Ang II in hypertension is further confirmed by clinical studies, where a
recent report suggests that AT1 receptor antagonists significantly reduce oxidative
stress and improve endothelial function in hypertensive patients [49]. Involvement of
oxidative stress in the pathology of hypertension was reported in humans with
essential hypertension [50-52], as well as in animal models like spontaneous
hypertensive rat (SHR) [53] and the Dahl salt-sensitive rats [54]. Moreover, Vaziri et
al. (2000) [55] demonstrated that in vivo glutathione depletion results in increased
oxidative stress followed by elevated blood pressure in normotensive rats. Similarly,
elevation in vascular O2-⋅ production was not only observed after Ang II infusion [56,
57], but also in other models of hypertension, like the two-kidney/one-clip [58], the
one-kidney/one-clip [59] and the renin transgenic model [60]. Pathophysiological
mechanisms underlying oxidative stress in these animal models is unclear, but
mechanical factors, such as blood pressure, may play a role, because the elevated
blood pressure itself increases NADPH oxidase generating- O2-⋅ in vasculature [61].
On the other hand, it was found that in vivo administration of membrane–permeable
SOD distinctly reduced the elevated blood pressure in SHR [62] and Ang II-infused
rats [48, 63].
2.3.1. Enzymatic sources of ROS
Several enzymatic sources of ROS have been suggested. For example, NOS,
the enzyme responsible for NO production can also generate O2-⋅
 under conditions of
substrate (L-arginine) or co-factor (tetrahydrobiopterin) (BH4) deficiency [64]. These
have led to the concept of ‘‘NOS uncoupling’’, where the activity of the enzyme for
NO production is decreased in association an increase in NOS-dependent O2-⋅
formation. Ang II may play a crucial role in these processes in pathological conditions
[57]. eNOS uncoupling has been reported in atherosclerosis [65], diabetes [66], and
hypertension [67], all of which are associated with increased level of ROS. Moreover,
xanthine oxidase, cytochrome P450, mitochondrial respiratory chain enzymes, and
phagocyte-derived myeloperoxidase are capable to generate ROS in the vasculature
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[22, 23, 68]. Nevertheless, the contribution of these enzymes to vascular generation
of ROS is relatively minor compared with NADPH oxidase.
2.4. NADPH Oxidase
2.4.1. The phagocyte NADPH oxidase model
The structure and function of NADPH oxidases are well characterized initially
in phagocytes where two membrane components, p22phox and gp91phox, form the
cytochrome b558. The catalytic subunit of this cytochrome, gp91phox, binds three
prosthetic groups, one flavin adenine dinucleotide (FAD) and two heme molecules.
The appropriate cytoplasmic protein complex is composed of p47phox, p67phox and
p40phox, and include the small regulatory-protein Rac [69]. The function of the
p40phox subunit, which is not essential for the oxidase activity, is a matter of debate
[70-73]. Agonist exposure leads to the assembly of cytoplasmic components followed
by their activation, which depends on the production of phosphotadic acid by
phospholipase D. In addition, protein kinase C (PKC)-dependent phosphorylation of
p47phox leads to conformational rearrangement and translocation of the cytosolic
subunits to the membrane. The activation process of the protein complex also
includes guanine nucleotide exchange of Rac-GDP to form Rac-GTP [70]. This
activated cytoplasmic complex then associates with the cytochrome in the membrane
to form a functional enzyme. The reduced substrate nicotinamide dinucleotide
phosphate (NADPH) binds to gp91phox on the intracellular side of the membrane
and releases two electrons, which are passed in turn to FAD, followed by transition to
the first and second heme group. Finally, the electrons are successively transferred
to molecular oxygen on the extracellular side of the membrane producing two
superoxide radicals. Once O2-⋅ is generated, it is metabolized enzymatically or non-
enzymatically into various ROS viz. H2O2, OH
- and hypochloric acid. The phagocyte
NADPH oxidases produce a large quantity of O2-⋅,
 and this contributes to the host
defence mechanism [69].
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2.4.2. Vascular NADPH oxidases
The biochemical characteristics of the vascular NADPH oxidases are
considerably different from those of the NADPH oxidase in neutrophils. It has been
demonstrated that the capacity of the vascular enzymes for O2-⋅ production is about
one-third that of the neutrophil [74]. It has been also verified that the catalytic subunit
gp91phox is only one member of a new family of homologous proteins termed Nox
[75-78]. Hence, it is very likely that all Nox family members transfer electrons from a
reduced substrate to molecular oxygen in a similar way (Fig.2.2.). As Compared to
the Nox enzymes, the Duox family is characterized by N-terminal extracellular
domains and an additional transmembrane domain and twice of size of the Nox
proteins [77]. Thus, the name Duox stands for dual oxidase (NADPH oxidase +
peroxidase). Two human Duox enzymes (Duox1 and 2) have been identified. Duox1
is found mainly in thyroid gland therefore, it is also called thyroid oxidase 1. However,
the RNA of Duox1 could be detected in lung, placenta, testis and prostate [79].
Duox2 is expressed, beside the thyroid gland in colon and small intestine [80].
Fig. 2.2. Schematic diagram shows the biochemistry and the generalized
molecular structure of NADPH oxidases. Electron flow (indicated by arrows)
proceeds from reduced NADPH to FAD, to heme (Fe) and finally to molecular
oxygen (O2) yielding O2-⋅
 (adapted from Bengtsson et al. (2003) [81]).
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2.4.2.1. The Nox proteins
The Nox family consists of close homologues of gp91phox, sharing their
presumed six transmembrane domains and their long intracellular C-terminus. Five of
the Nox family are known in human. Nox1 refers to the enzyme originally described
as Mox1 [78]. The main site of expression is the colon epithelium [82]; minor sites of
expression include prostate, uterus and VSMCs [75, 78]. Surprisingly, Nox1 was not
expressed in VSMCs from resistance arteries [23]. So far, there is only one report of
Nox1 mRNA expression in human endothelial cells and cardiac fibroblasts [83]. The
term Nox2 is used as a synonym for gp91phox is predominantly expressed in
granulocytes and monocytes/macrophages; minor sites of expression include B-
lymphocytes [84], mesangial cells [85], and endothelial cells. Nox3 is solely found in
the fetal kidney [82]. Nox4, initially termed as Renox (renal oxidase), is mainly
expressed in the kidney cortex [86]. The Nox4 subunit was abundantly expressed in
all vascular cells as mRNA [83] as well as protein in aortic lysate [87]. Finally, Nox5 is
distinguished from the other family members by its longer N-terminus. It is found in
testis and B and T-lymphocyte rich area of spleen and lymph nodes [88]. Nox
isoforms are summarized in table 2.1.
Table 2.1: Nox isoforms
Isoform Vascular Non-vascular
Nox1 VSMCs [87, 89], endothelial cells
[83]
Epithelial cells (colon [82]
uterus and prostae [75, 78])
Nox2 Endothelial cells [56, 90], Neutrophils, B-lymphocytes
[84] and mesangial cells [85].
Nox3 Fetal tissues [82].
Nox4 All vascular cell types [83]. Kidney [86].
Nox5 Lymph nodes and spleen [88].
Duox1 Thyroid, lung, placenta, testis
and prostate [79, 80].
Duox2 Thyroid, colon and small
intestine [80].
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2.4.2.2. Expression of vascular NADPH oxidases in cells and
tissues
Previous investigations on the origin of vascular ROS demonstrated that
NADPH oxidase is a major source of O2 -⋅ formation. The enzymatic activity was
found in all layers of the vessel wall (endothelium [91], media [92], adventitia [93]) as
well as in cultured VSMCs [89]. Since this enzyme shared some features with the
phagocytic oxidase, researchers attempted to demonstrate the presence of
phagocytic NADPH oxidase subunits in the vessel wall, particularly the major four:
gp91phox, p22phox, p47phox, and p67phox [94].
Intima and Adventitia
 In the endothelium, expression of the mRNA of all subunits has been
demonstrated [95]. These results are confirmed by detection of all four proteins using
Western blotting analysis [96] and immunohistochemistry [97]. In the adventitia, the
four major phagocytic subunits were also detected by immunohistochemistry [98]. In
addition, p22phox and gp91phox proteins were found in about 25-30% of intimal
smooth muscle cells in non-diseased regions of human aorta [99].
Media
In the media, the situation is more complicated, because phagocytic subunits
have been not found at all. The presence of p22phox subunit in VSMCs was
demonstrated using molecular cloning [100] and Western blotting [23]. The other
major phagocytic oxidase subunits, p67phox and gp91phox are either very low or
undetectable in aortic VSMCs and media [99, 101]. In contrast to cells from large
vessels, VSMCs from human resistance arteries reveal mRNA and protein of all
major phagocytic NADPH oxidase subunits [23], In this context, it should be
mentioned that translocation of p67phox from the cytosolic to the particulate fraction
is observed following to Ang II stimulation and blocking O2-⋅ production by gp91phox
antisense oligonucleotides [23]. Also, the vascular NADPH oxidase may be
differentially regulated in conduit and resistant arteries.
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2.4.2.3.Biochemical characteristics of vascular NADPH oxidases
Low and constitutive activity
The rate of O2 -⋅ production in vascular cells is thought to be 1 to 10% of that in
leukocytes [102]. As it might be expected from the cytotoxicity of superoxide, the
phagocytic NADPH oxidase enzyme is inactive in the absence of stimuli [69, 70]. In
order to observe the enzyme activity in homogenized neutrophils, it is therefore
necessary to add a cytosolic fraction with p47phox and p67phox to the membrane
fraction containing cytochrome. In contrast, oxidase activity was observed in isolated
membrane fractions of unstimulated vascular cells [98] and moreover, enzyme
activity is inhibited by addition of cytosolic fractions [103]. This constitutive activity
can be explained by detection of p47phox and p67phox proteins in the particulate
fraction of vascular cells [23, 98].
Induced activity
Vascular NADPH oxidases are constitutive enzymes, but they can be also
regulated by humoral factors, such as Ang II [89], platelet-derived growth factor [104],
thrombin [105], tumour necrosis factor-µ (TNF-µ)[106], and glucocorticoids [107].
Although the vascular enzymes are activated after few minutes of stimulation [108],
their activity can also be markedly upregulated after hours of exposure to agonists.
Thus, the rate of O2-⋅ production was increased two to three-fold in VSMCs-exposed
to Ang II for 4-8 h[103]. This effect probably results from the increased expression of
NADPH oxidase [101]. Indeed, new protein synthesis was required for upregulation
of oxidase subunits in VSMCs exposed to Ang II for 2 h [23].
2.4.2.4. Activation pathways of NADPH oxidases
PKC
Since phosphorylation of the p47phox subunit by PKC is required for
activation of the phagocytic oxidase, several studies have investigated the role of this
kinase in activation of the vascular oxidases. Accordingly, treatment of VSMCs with
PKC inhibitors reduces ROS production after stimulation by platelet derived growth
factor (PDGF) or Ang II [107, 108]. Furthermore, TNF-µ-induced translocation of
p47phox in endothelial cells is inhibited by the PKC inhibitor chelerythrine [109]. It is
noteworthy that the effect of PKC inhibition is usually partial, especially after
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exposure to the agonist for longer periods [108], suggesting different pathways of
enzyme activation. However, PKC activation may have long-lasting effects on ROS
production because upregulation of the oxidase subunits was also reported [101].
Phospholipase D
The possibility that lipid metabolites involved in signaling might activate the
vascular oxidases was a subject of several investigations. Exogenous phosphatidic
acid significantly increased oxidase activity in intact VSMCs and homogenates [110].
In addition, incubation of VSMCs with sphinganine or suramin, which are non-specific
inhibitors of phospholipase D, leads to Ang II-induced ROS formation [111, 112].
Phospholipase A2
In vitro study, it has been has demonstrated that the phagocytic oxidase could
be activated by the addition of fatty acids. Similarly, in VSMCs homogenates,
exogenous arachidonic acid and linoleic acid specifically increased NADPH oxidase
activity [89, 113]. Free fatty acids, together with phospholipase, are produced in cells
after agonist activation of phospholipase A2 suggesting that this enzyme might
activate NADPH oxidases.
2.4.2.5. NADPH oxidases and vascular diseases
Atherosclerosis
O2-⋅ is presumed to participate in atherogenesis is through the formation of
oxidized lipids, particularly oxidized low-density lipoportein (LDL). The altered
bioactivity of oxidized compared with unoxidized LDL was first reported by Hessler et
al. (1983) [114]. It has been demonstrated that activated monocytes could oxidize
LDL [115, 116]. This was found to be a unique activity of leukocytes, because they
are the only cells which can oxidize LDL in the absence of free metal ions [117].
Macrophages-mediated LDL oxidation was shown to be dependent on the production
of O2-⋅ by the NAD(P)H oxidase enzyme complex [117, 118]. There is substantial
evidence that elevated NAD(P)H oxidase activity is closely linked with atherogenesis
and vascular remodeling after balloon angioplasty. It has been shown that NAD(P)H
oxidase activity is upregulated with intimal hyperplasia induced by periarterial collars
[119], hypercholestremia and arterial balloon injury [120]. Increased NAD(P)H
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oxidase activity is also linked to clinical risk factors concerning atherosclerosis and
impaired eNOS function in patients with coronary artery disease [121]. Studies
examining expression of oxidase subunits during atherogenesis consistently
demonstrate that although gp91phox is upregulated, Nox4 expression remains
relatively unchanged throughout lesion development [119]. In atherosclerotic lesions
Nox4 was highly expressed with Nox1 and p22phox and produced O2-⋅, suggesting a
crucial role for Nox4 in atherosclerotic lesions [83]. NAD(P)H oxidase has been
investigated for its contributions to the development of arthrosclerosis in mice. Three
studies have been performed in animals with gene knockout of either of 2
components of this enzyme complex (p47phox or gp91phox) [122, 123]. All three
studies indicate that NADPH oxidase has a little or no effect on the development of
atherosclerosis. However, a recent study performed by Barry et al. (2001) [122, 124]
showed that crossing genetically hypercholesterolaemic apolipoprotein E-knockout
(Apo E -/-) mice with p47phox-dificient mice reduces the area of the descending
aorta covered by lesions by a staggering 80%, regardless of whether the animals
were fed by a standard chow or high fat diet. This demonstrates that increased
NAD(P)H oxidase activity is not just a symptom of atherosclerosis, but a causative
factor in pathogenesis of the disease.
Experimental hypertension
In DOCA–salt induced hypertension, an enhanced vascular O2-⋅ production
with impaired endothelium-dependent relaxation was observed [125]. Wu et al.
(2001) [126] have reported that the enhanced superoxide production in the aorta of
DOCA-salt hypertensive rats was associated with an increased Nox activity.
Moreover, Heitzer et al. (1999) [58] showed that increased aortic O2-⋅ generation in
renal hypertension model was associated with over-activity of NADPH oxidase.
Genetic hypertension
An early study performed by Suzuki et al. (1995) [53] described an increase in
O2-⋅ generation in venules and arterioles of spontaneous hypertensive rats (SHR).
Recently, it has been shown that enhanced NADPH oxidase–mediated O2-⋅
production is associated with upregulation of p22phox mRNA expression and
development of endothelial dysfunction in the aorta of adult SHR [127]. In contrast, in
norepinephrine-induced hypertension, neither O2-⋅ production nor NADPH activity is
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enhanced [128]. Interestingly, p22phox mRNA expression and Nox activity was
normalized after treatment with AT1 receptor antagonist irbesartan, indicating a
critical role of Ang II in the upregulation of Nox in adult SHR [127]. Additionally, an
enhanced expression of AT1 receptor and ACE has been reported in vessels of adult
SHR [129]. In addition it was demonstrated that apocynin, a specific inhibitor of
NADPH oxidase subunit assembly, decreases the enhanced O2-⋅production in the
aortic wall of 9 to 12 month-old SHR stroke prone, suggesting a potential role of
NADPH oxidase in vascular generation of O2-⋅ in this model of hypertension [130].
2.4.2.5. Activation of vascular NADPH oxidases by Ang II
A growing body of evidence indicates that NADPH oxidases are activated by
mechanical forces (shear stress), hormones and cytokines [22, 47]. Ang II is widely
accepted as an important activating stimulus for vascular NADPH oxidases. Griendling et
al. (1994) [89] showed that pathophysiologically relevant concentrations of Ang II
increased NADPH oxidase activity in rat VSMCs. In VSMCs, Ang II stimulates formation
of ROS primarly via activation of the multisubunits enzyme NADPH oxidase [70]. ROS
seems to play a crucial role in Ang II signaling in vasculature. Supporting this hypothesis,
Ang II is related to produce ROS in vascular cells, while antioxidants and inhibitors of
ROS-generating system abolish agonist-mediated signaling pathways. Transcription
factors [131], protein tyrosine phosphatases [132], protein tyrosine kinases [131],
mitogen-activated protein (MAP) kinases and ion channels [133](56) have been
demonstrated to be regulated by ROS produced by  Ang II (Fig. 2.3.).
 Although mechanisms linking Ang II to the enzyme as well as upstream signaling
molecules modulating NADPH oxidase in vasculature have not been fully elucidated,
phospholipase D and PKC are suggested to be involved [111, 112]. In this context, it has
been demonstrated that the upstream activator of epidermal growth factor (EGF)
receptor transactivation, c-Src, plays an important role in the sustained Ang II-mediated
activation of NADPH oxidase in VSMCs [108]. Furthermore, c-Src has been found to
regulate NADPH oxidase-derived O2-⋅ generation by stimulating phosphorylation of
p47phox in Ang II-treated VSMCs [134].
Activation of NADPH oxidase by Ang II have been shown in several clinically
relevant animal models of disease. Ang II-induced hypertension in rats is associated with
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a distinct increase in vascular O2-⋅ production [48, 135, 136]. These responses seem to
be mediated by activation of the AT1 receptor, because they could be normalized by
administration of losartan [136]. Moreover, Ang II-induced hypertrophy was abrogated by
DPI [89].  In addition, catalase overexpression attenuated the Ang II-induced effects on
growth [137]. Finally, in cardiac myocyte, Ang II- and TNF-µ-induced hypertrophy was
associated with an intracellular release of ROS [138, 139].
Fig. 2.3. Signaling pathways by Ang II in VSMCs. Ang II stimulates formation of
ROS primarily via activation of the multisubunits enzyme NADPH oxidase.
Intracellular ROS modulate the activity of tyrosine kinases and activate MAP
kinases. ROS also influence gene and protein expression by activating
transcription factors. ROS stimulate ion channels, such as plasma membrane
Ca+2 and K+, producing changes in cation concentrations. Activation of these
redox-sensitive pathways results in several cellular responses (adapted from
[140]).
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2.4.2.6. Regulation of the vascular NADPH oxidase subunits by Ang
II in vitro and in vivo
P22phox
Numerous studies have shown that the oxidase subunits are frequently
upregulated after Ang II treatments leading to increased ROS production. For
example, a recent study by Rueckschloss et al. (2002) [141] showed that the
p22phox mRNA was elevated in endothelial cells-exposed to Ang II. Antisense RNA
of p22phox, inhibits its expression as well as decreased Ang II-induced O2-⋅
production, indicating that p22phox is a required component of the vascular oxidase
[142]. Moreover, it has been demonstrated that the mRNA level of p22phox was
upregulated in the aorta of rat chronically infused with Ang II [57, 143]. Besides, a
simultaneous decrease in blood pressure, vascular oxidase activity and expression of
p22phox mRNA has been observed by treatment of Ang II-infused rats with the PKC
inhibitor chelerythrine [57] or with AT1 receptor antagonists [143, 144].
P67phox, p40phox and p47phox
In vitro studies, it have been shown that Ang II upregulates p67phox mRNA
expression and the oxidase activity in endothelial cells [141] and adventitial fibrocytes
[145]. Immunodepletion of p67phox, blocks the oxidase activity in fibrocytes [98].
However, this effect can be reversed by addition of recombinant protein [98]
indicating that p67phox is a functional part of the fibrocytic enzyme.  In VSMCs from
resistance arteries, Ang II upregulated proteins of all phagocytic oxidase subunits
[23]. This is the first report that points to a functional role of p40phox in vascular cells.
In VSMCs and endothelial cells of p47phox-deficient mice, Ang II-mediated signaling
and ROS production was significantly reduced [146]. Additionally, electroporation of
p47phox antibodies inhibits Ang II-induced ROS production in VSMCs [147].
Cifuentes et al. (2000) [56] have demonstrated that the p67phox protein is
upregulated in aortic adventitia of mice after Ang II infusion for 7 days. In this context,
a cell-permeable decoy peptide has been designed to using the p47phox sequence
necessary for binding to gp91phox [148]. In the following rudimentary tests using
aortic rings, this peptide abolished Ang II-induced O2-⋅ production. Apart from
blocking the peptide vascular O2-⋅ production, it has also inhibited the increase in
blood pressure induced by a 7-day Ang II infusion [148]. It has also been reported
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that disruption of the p47phox gene abolishes the elevation of vascular superoxide
and markedly reduces the increase in blood pressure in mice infused with Ang II for 7
days [146]. These findings together with the results described by Wang et al [90],
indicate that p47phox is an essential component of the vascular NADPH oxidase
controlling the development of Ang II-induced hypertension.
gp91phox (Nox2)
 Recent studies show that Ang II increases O2-⋅ production and gp91phox
mRNA levels in endothelial cells [141, 149, 150] as well as in rat aorta [57].
Furthermore, both gp91phox mRNA and protein were increased in the aortic
adventitia of mice after Ang II infusion [56, 90]. Blocking of AT1 receptors decreased
gp91phox mRNA expression in endothelial cells [57, 141] and in internal mammary
artery of patients with coronary heart disease [141]. In rat, administration of
chelerythrine, which inhibited Ang II-induced hypertension, also prevented gp91phox
upregulation [57].
Although basal blood pressure is diminished in gp91phox-deficient mice-
infused by Ang II, absence of gp91phox does not reduce the hypertensive effect of
the agonist [90]. In addition, deletion of the gp91phox gene does not inhibit Ang II-
induced adventitial nitrotyrosine accumulation and aortic media thickening [135, 151].
Recently, it has been shown that cardiac hypertrophy caused by subpressor infusion
of Ang II is attenuated in mice deficient in gp91phox, suggesting involvement of this
isoform in myocardial hypertrophy [152]. However, contrasting roles of NADPH
oxidase isoforms in pressure overload and to Ang II-induced cardiac hypertrophy
have been reported [153].
Nox1 and Nox4
It has been shown that antisense to Nox1 mRNA completely inhibited Ang II-
induced O2-⋅ production in VSMCs, supporting the role of Nox1 in redox signaling in
VSMCs. [101]. This study also reported that Ang II upregulates the Nox1 mRNA
expression levels in these cells. In contrast, treatment with atrovastatin decreased
both, ROS production and Nox1 mRNA expression [154]. Since VSMCs from large
arteries express little or no gp91phox, Nox1 therefore, seems to be an essential part
of the oxidase as well as functional substitute for gp91phox in VSMCs. However,
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contrary results probably due to different cell lines and respective exposure to serum
before starting experiments have been observed [87, 101]. Nox4 has recently been
reported to be the major catalytic component in endothelial cells [155]. In rats made
hypertensive by the renin gene overexpression or infusion of Ang II for 7 days, Nox1
mRNA expression was markedly upregulated [57, 87], and the Nox4 mRNA and
protein was also increased to a lesser extent in aorta and kidney [87]. After in vivo
administration of chelerythine, the increase in Nox1 mRNA expression levels and
blood pressure due to Ang II infusion is markedly reduced [57].
However, to date, nothing is known about the in vivo regulation of Nox1 and Nox4 via
Ang II receptors (AT1A or AT2) during normal physiology.
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3. Aims of the Study
 Several studies suggest that AT2 receptors might oppose the actions of the
AT1 receptors with respect to blood pressure, vascular tone and cellular proliferation
under pathological condition. Whether Ang II receptors are also counter-regulatory in
regulation of NADPH oxidase and vascular tone under physiological conditions is not
known. Considering the increasing use of AT1 receptor blockers clinically, it would be
interesting and therapeutically important to understand the regulation of NADPH
oxidase isoforms particularly Nox1 and Nox4 and vascular tone by Ang II under
physiological conditions. Therefore, in the present study, we took advantages of mice
with gene-targeted mutations in the AT1A or AT2 receptors (AT1A
-/- or AT2
-/Y mice,
respectively) as powerful tools to examine:
1. The expressional regulation of Nox1 and Nox4 by AT1A and AT2 receptors under
physiological levels of Ang II.
2. The relative contribution of these receptors to NADPH oxidase activity or vascular
functions.
3. The interplay between Ang II receptors (AT1A and AT2) and NO signaling pathways
involving eNOS and sGC protein expression and its functional relevance by the way
of endothelium dependent and independent vascular relaxation in isolated aortic
rings from mice- deficient in AT1A or AT2 receptors.
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4.Materials
4.1. Antibodies
Primary antibody Dilution Secondary antibody Dilution
Nox1 (rabbit):  Peptides-
antibodies, polyclonal
antibody.
1: 25000
(Advanced ECL)
Goat anti-rabbit conjugated to
horseradish peroxidase
(DAKO, Denmark).
1: 20000
Nox2 (rabbit): polyclonal
conjugated, synthetic
peptide corresponding to
amino acids 548-560 of
human gp91phox.
1: 2000
(Advanced ECL)
Goat anti-rabbit conjugated to
horseradish peroxidase
(DAKO, Denmark).
1: 20000
Nox4 (rabbit)
Peptides-antibodies,
polyclonal aantibody.
1: 10000
(Advanced ECL)
Goat anti-rabbit conjugated to
horseradish peroxidase
(DAKO, Denmark).
1: 20000
sGCa1 (rabbit)
Polyclonal human sGCa1
affinity-purified against the
sGCa1peptide (residues
634-647).
1: 6000
(Normal ECL)
Goat anti-rabbit conjugated to
horseradish peroxidase
(DAKO, Denmark).
1: 2000
sGCb1(rabbit)
Polyclonal human sGCb1
affinity-purified against the
sGCb1peptides (residues
593-614).
1: 4000
(Normal ECL)
Goat anti-rabbit conjugated to
horseradish peroxidase
(DAKO, Denmark).
1: 2000
anti-nitrotyrosine (rabbit)
polyclonal antibody.
1: 1000
(Normal ECL)
Goat anti-rabbit conjugated to
horseradish peroxidase
(DAKO, Denmark).
1: 2000
eNOS (mouse)
anti-eNOS monoclonal
antibody.
1: 2500
(Normal ECL)
Anti-mouse: peroxidase
conjugated from goat (DAKO,
Glostrup, Denmark).
1: 2000
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4.2. Chemicals
Chemical Producer
b-Mercaptoethanol Carl Roth Gmbh (Karlsruhe)
Acetylcholine Sigma (Deisenhofen)
Acrylamide (30%) with 0.8%
Bisacriamid
Carl Roth Gmbh (Karlsruhe)
Apocynin CALBIOCHEMA
APS Merck (Dramstadt)
Bovine serum albumin (BSA) Sigma (Deisenhofen)
CaCl2 Merck (Dramstadt)
Complete EDTA free (protease inhibitor
set)
Roche Molecular Biochemicals
(Mannheim)
DPI Kingeston, Ontario,Canada
EDTA Sigma (Deisenhofen)
EGTA Sigma (Deisenhofen)
Ethanol Merck (Dramstadt)
Folin-Chiocateu,s phenol reagent Merck (Dramstadt)
Glucose Carl Roth Gmbh (Karlsruhe)
Glycine Carl Roth Gmbh (Karlsruhe)
HEPES Sigma (Deisenhofen)
HPR-Immunoglobulin (ant-rabbit) DAKO (Hamburg)
KCl Carl Roth Gmbh (Karlsruhe)
KH2PO4 Carl Roth Gmbh (Karlsruhe)
L-NAME Sigma (Deisenhofen)
Methanol Merck (Dramstadt)
MgSO4.7H2O Merck (Dramstadt)
NaCl Merck (Dramstadt)
NaHCO3 Merck (Dramstadt)
NaNO2 Merck (Dramstadt)
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NaOH Carl Roth Gmbh (Karlsruhe)
Oxypurinol Sigma (Deisenhofen)
Phenylehrine Sigma (Deisenhofen)
SDS Carl Roth Gmbh (Karlsruhe)
sGCa1 Produced in our lab
sGCb1 Produced in our lab
SOD Sigma (Deisenhofen)
Sodium Pyrophosphate Sigma (Deisenhofen)
Spermine NONOate Alex is  cooperat ion (Lausen,
Switzerland)
Sucrose Sigma (Deisenhofen
TEMED Sigma (Deisenhofen)
Tris Carl Roth Gmbh (Karlsruhe)
Triton X-100 Serva Feinbiochemica (Heidelberg,
Germany
Water was deionised to 18 MW cm (Milli-Q;Millipore, Eschborn)
4.3. Software
Software Version Producer
Adobe Acrobat 4.0 Adobe system (San Jose, CA, USA)
Adobe Photoshop 7.0 Adobe system (San Jose, CA, USA)
EndNote 6.0 ISI research software (Berkeley ,CA
USA)
IBJ-BeMon 32 PowerLab, Germany
Kodak ID Image analysis
software
Eastman Kodak company (New
Haven, USA)
Microsoft office Mac 2002 Microsoft Coperation  (Remond, WA,
USA)
Graph Pad Prism 3.0/4.0 Graph Pad Software (San Diego,
Ca, USA)
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5. Methods
5.1. Tail cuts and earmarks
In our present study, potential transgenic mice are screened for the presence
of gene by performing polymerase chain reaction (PCR) with a DNA sample
extracted from the tail biopsy. When the tail biopsy was performed, the sample was
assigned with identification number and the mouse is marked with that number. In
Fig. 5.1., we show how to mark a mouse by ear punching. This scheme allows mice
to be numbered from 1 to 99 and is sufficient for most purposes when combined with
cage card identification including also sex and age.
Fig. 5.1. A scheme for marking a mouse by ear punching, using a continuous
number system from 1 to 99.
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5.2. Isolation of mouse genomic DNA from tail biopsies
Isolation of genomic DNA was performed by two methods.
5.2.1. Using DNeasy tissue kits (Qiagen, Germany)
1. We cut up to 0.4 - 0.6 cm length of tail into a 1.5 ml microcentrifuge tube and 180
µl of buffer ATL were added.
2. We added 20 µl of proteinase K, mixed well by vortexing, and incubated at 55°C
over night for complete lysis.
3. After a short vortex (15 second), 400 µl of buffer AL-ethanol mixture was added to
the sample, and mixed vigorously by vortexing.
4. Then, this mixture was pipeted into the DNeasy spin column and placed in a new 2
ml collection tube and centrifuged at 8000 rpm for 1 min.
5. After, the DNeasy mini spin column was placed in a new 2 ml collection tube, 500
µl of buffer AW1 was added and centrifuged at 10000 x g for 1 min.
6. Next, we placed the DNA spin column in a new 2 ml collection tube, and 500 µl of
buffer AW2 was added, which was followed by centrifugation for 3 min at full speed
(14000 rpm) to dry the DNeasy membrane.
7. Finally, the DNeasy mini spin column was placed in a clean 1.5 ml or 2 ml micro-
centrifuge tube and 200 µl of buffer AE was directly added into the DNeasy
membrane for the elution of DNA. Then, this was incubated at room temperature for
1 min, and centrifuged for 1 min at 10000 x g  to elute.
5.2.2. Using special lysis buffer
50 mM             KCl
1.5 mM            MgCl2
10 mM             Tris-Hcl, pH 8.3
0.45%              Nonidet P 40
0.45%              Tween 20
100 µg /ml       Proteinase K
Procedure
Add about 400 µl of this lysis buffer (mentioned above) to a tail cut and lyse at
55°C for overnight with continuous shaking. Then, we heated to inactivate the
proteinase K at 94°C for 20 min. After spin down the condensation, samples were
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briefly centrifuged (3 min, 8000 x g), and the supernatant was separated in sterile
eppendorf tube.
5.3. Determination of DNA yield
The DNA yield was determined by measuring the concentration of DNA in the
elute by its absorbance at 260 nm (A260) using spectrophotometer (Pharmacica LKB.
Biochrom 4060).  Absorbance readings at 260 nm should fall between 0.15 and 1.0
to be accurate. An A260 of 1 (with a 1 cm detection path) corresponds to 50 µg DNA/1
ml water. Distilled water should be used as diluents when measuring DNA
concentration since the relationship between absorbance and concentration is based
on extinction coefficient calculated for nucleic acids in water [156]. Using a 0.1 ml
cuvette, the absorbance of the diluted sample was measured.
An example of calculations involved in DNA quantification is shown below:
Volume of DNA sample = 100 µl
Dilution                          = 10 µl of DNA sample + 90 µl of distilled water
Concentration of DNA   = 50 µg / ml x A260 x dilution factor
                                      = 50 µg / ml x A260 x 10
5.4. Generation and genotyping of AT1A receptor-deficient mice
5.4.1. Generation of AT1A
-/- mice
Male and female heterozygous AT1A
+/- mice were produced by Jackson
laboratories (USA) and mated to get homozygous mice. The founder strains were
developed by Coffman et al. (1995)[26]. Mice of F2 progeny were derived from mating
between 129X and C57Bl/6j from the F1 AT1A heterozygous parents. The F2
generation of AT1A
+/+ and AT1A
-/- had similar random assortment of background
genes, making them appropriate matches for our study. Animals were bred and
maintained Animals were bred and maintained in isolated ventilated cages under
specificed pathogen-free conditions according to the recommendations of Federation
of European Laboratory Animals Science Association (FELASA) in isolated ventilated
cages under specified pathogen-free conditions.
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5.4.2. Genotyping of AT1A
-/- mice
The genotyping of mice in the present study was performed by PCR. PCR
technique is designed for amplification of specific regions of DNA using Taq DNA
polymerase. Taq polymerase is a thermostable enzyme isolated from Thermus
aquaticus.
Materials:
DNA-agarose gel loading buffer
0.25% (w/v)      Bromophenolblue
0.25% (w/v)     Xylencyanol
30%                 glycerol in water
TAE-buffer
40 mM              Tris-HCl
2 mM                 EDTA
0.1% (v/v)         CH3COOH (Eissig).
Markers
1kb-DNA (Eurogenetic, Seraing, Belgium)
Primers
Upstream    (5`-ACCAACTCAACCCAGAAAAGC-3`)
Downstream (5`-CCAGGATGTTCTTGGTTAGG-3`)
Protocol
Buffer S (10x) (PeQlab)                      5 µl
dNTPs  (10mM)                                  1 µl
Upstream primer (50 pmol/ µl)            1 µl
Downstream primer (50 pmol/ µl)       1 µl
Taq-polymerase (5 U/ µl)                    0.25 µl
DNA template (100-200 ng)                X µl (depend on amount of DNA)
H2O (sterile and distilled) to                50 µl
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PCR Profile
Amplification 30 cycles
Activation Denaturation Annealing Elongation Termination
5 min 1 min 1 min 1.2 min 7 min ∞
95°C 95°C  55°C  72°C 72°C 4°C
 Procedure
To perform several parallel reactions, we recommended the preparation of a
master mix. In the master mix, all ingredients including buffer, dNTPs, primers and
Taq DNA polymerase were combined in a single tube. Then, the mixture was
aliquoted into individual thin-walled PCR tubes containing templates of DNA, on ice.
The master mix of setting reactions minimizes the possibility of pipeting errors and
saves time by reducing the number of reagent transfers. After tubes were gently
vortexed, we made a brief centrifugation (1000 x g for 2 min, 4°C). Then, tubes are
placed in the PCR thermo-cycler machine. The DNA products were amplified using
PCR profile (mentioned above) with appropriate number of cycles to be clearly visible
on an agarose gel. After amplification process, a 6-8 µl of DNA- agarose loading
buffer was added to each 50 µl of PCR product. Subsequently, the PCR products (20
µl) were loaded onto ethidium bromide-stained 1.2% agarose gel, at 100 volt for 50
min using 1-kb marker. Bands were visualized using a UV lamp  (UV
Transilluminator, Micro Bio Tech Brand, Germany) and imaging system (Kodak
EDAS 290, USA). The wt band (+) is detected at 620-bp, and the mutant band (-) is
detected at 1.2-kb sequences (Fig. 5.2.).
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Fig. 5.2. PCR analysis for AT1A receptor-deficient mice using 1-kb marker,
showing the mutant band could be detected at 1.2-kb and wt band at 620-bp.
5.5. Generation and genotyping of AT2 receptor-deficient mice
5.5.1. Generation of AT2
-/Y mice
Mice lacking AT2 receptors were originally produced by Hein et al. (1995)
[157]. Germline-transmitting chimeric mice were crossed back into an FVB/N
background for 8 generation. The Ang II AT2 receptor gene is located on the X
chromosome. Therefore, only wt (AT2
+/Y) and hemizygous (AT2
-/Y) male littermates (3-
4 months-old) derived from crossing of male wt FVB/N and heterozygous mice were
used in our present study. Animals were bred and maintained in isolated ventilated
cages under specificed pathogen-free conditions according to Federation of
European Laboratory Animals Science Association (FELASA) requirements.
5.5.2. Genotyping of AT2
-/Y mice
Primer-Sequences (in 5`to 3`direction)
wt "+" Primer:            5`-CCT TGG CTG ACT TAC TCC TT-3`
AT2 "-" Primer:           5`-GAA CTA CAT AAG ATG CTT GCC-3`
AT2-ko "-" Primer:      5`-TAG TTG CCA GCC ATC TGT TG-3`
Protocol
10x Buffer (Eppendorf)                               5 µl
AT2 -wt"+" Primer (50 pmol/µl)                   1 µl
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AT2 "-" Primer (50 pmol/µl)                        1 µl
AT2-ko "-" Primer ((50 pmol/µl)                  1 µl
dNTP (10 mM)                                           0.5 µl
Taq-Polymerase  5 U/ µl                            0.25 µl
DNA template (100-200 ng)                       X µl (depend on amount of DNA)
H2O (sterile and distilled) to                       50 µ
PCR-profile
Amplification 35 cycles
Activation Denaturation Annealing Elongation Termination
5 min 30 sec 30 sec 40 sec 7 min ∞
95°C 95°C 55°C 72°C 72°C 4°C
Procedure
All ingredients (water, buffer, dNTPs, primers and Taq DNA polymerase) were
combined to make master mix. Then, the mixture is aliquoted into individual thin-
walled PCR tubes containing templates of DNA, on ice. After tubes were gently
vortexed, we made a brief centrifugation (1000 x g for 2 min, 4°C). After a brief
centrifugation (15 sec), tubes were placed in the PCR thermo-cycler machine. The
DNA products were amplified using PCR profile mentioned above with appropriate
number of cycles to be clearly visible on an agarose gel. After amplification process,
a 6-8 µl of DNA- agarose loading buffer was added to each 50 µl of PCR products.
The PCR products (20 µl) were loaded onto ethidium bromide-stained 2% agarose
gel, at 100 volt for 50 min using 1-kb marker. Finally, bands were detected using a
UV lamp  (UV Transilluminator, Micro). The expected-PCR-Products were detected
at 234-bp for the wt allel and 383-bp for the mutant allel (Fig. 5.3.).
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Fig. 5.3. PCR analysis of AT2-receptor-deficient mice using a 100 bp marker. As
shown, the mutant (AT2
-/Y) band could be detected at 383-bp and wt (AT2
+/Y)
band at 234-bp.
Marker
100-bp-DNA (Eurogenetic, Seraing, Belgium)
5.6. Protein analysis
5.6.1. Tissues lysis for Western blots
Materials:
2x SLB (Special-Lysis- Buffer)
40 mM                  Tris-HCl pH 7.4
150 mM                NaCl
2% (w/v)               Na-deoxycholat
2% (v/v)                Triton X-100
0.1 (w/v)               SDS
50 mM                  EDTA
50 mM                  EGTA
50 mM                   Na-pyrophosphate
2 mM                     Vanadat
2x                          Protease inhibitor complete EDTA free (Roche)
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Rotiload buffer
62.5 mM                Phosphate buffer (pH 6.8)
10% (v/v)              Glycerol
2% (w/v)                SDS
0.01% (w/v)           Bromophenol blue
5% (v/v)                 2-Mercaptoethanol
Procedure
For Western blotting analysis, mice were sacrificed by cervical dislocation.
Aorta and other organs were excised rapidly, and the fat or connective tissues were
manually removed under a binocular microscope. Tissues were washed with normal
saline and immediately frozen in liquid nitrogen, and stored in –80°C.  The frozen
tissues were powdered and an amount of 40 - 45 mg of the powdered tissue was
transferred to a 1.5 ml eppendorf tube. For tissue lysis, about 350 µl of 2x SLB lysis
buffer (mentioned above) was added to the powdered tissue. Because liver contains
more proteins compared to other organs, we added about 400 µl of lysis buffer to 40
– 45 mg powdered tissue from liver. The mixture was vortexed, and further mixed for
10 min using an eppendorf mixer. Following which, the same volume of 2x rotiload
buffer was added and boiled for 15 min at 95°C in eppendorf thermo-mixer. The
mixture was centrifuged at 8000 x g for 10 min, and the supernatant was transferred
to fresh eppendorf tubes without touching the pellets. After protein precipitation with
trichloroacetic acid, protein concentrations were determined by the Lowry method
[158].
5.6.2. Protein determination
Materials:
Folin I reagents for Lowry-protein determination
Folin I reagent is a mixture of A to D in ratio 1: 1: 28: 10, respectively.
Solution A
1% (w/v) CuSO4
Solution B
2% (w/v) Na-Tartrate
Solution C
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3.4% (w/v) NaCO3 in 0.2 M NaOH
Solution D
10% (w/v) SDS
In samples with rotiload buffer for SDS-PAGE, protein was determined
according to Lowry method after precipitation of protein by trichloroacetic acid [158].
Different concentrations of BSA (0.0 mg, 0.1 mg, 0.2 mg, 0.4 mg, 0.8 mg 1.6 mg 2.4
mg and 3.2 mg / ml distilled water) were prepared. 50 µl volume of BSA- standards,
and 10 µl of protein extract were diluted with 1 ml of distilled water and 100 µl of
0.15% deoxycholic acid was added. After 10 min incubation at room temperature on
eppendorf shaker, 100 µl of 72% trichloroacetic acid was added, and incubate for 15
min with shaking at room temperature. Then, samples and standards were
centrifuged at 16000 x g for 10 min.  After aspiration of the supernatant, pellets were
resuspended in 300 µl water and 300 µl of Folin 1 reagent (see above) was added,
and incubated for 10 min with shaking at room temperature. Subsequently, 150 µl of
25% (v/v) Folin-Ciocalteus-Phenol reagent (diluted to 1: 3 with water) was added to
samples as well as standards and incubated for 30 min with shaking. Finally, a
volume of 300 µl was twice pipeted into a 96-well plate. The protein concentration
was measured at 595 nm using a spectraMax 340 (Molecular Devices). BSA protein
standards were used to calculate the concentration of protein from its optical density.
5.6.3. SDS-Polyacrylamid-gelelectrphoresis (SDS-PAGE)
Materials:
Electrophoresis buffer
25 mM               Tris.HCl
120 mM              Glycin
0.1%                   SDS
SDS-gel (9%)
Separation gel Collection gel
9% (v/v) AA-Bis 5 % (v/v) AA-Bis
750 mM Tris/Hcl, pH 8.8 625 mM Tris/Hcl,pH 6.8
0.1% (v/v) SDS 0.1% (v/v) SDS
0.05% (v/v) TEMED 0.1% (v/v) TEMED
0.07% (w/v) APS 0.05% (w/v) APS
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Protein markers
BOA-protein marker (Biomol, Hamburg).
Equal amounts of protein (50µg) were run on 9% polyacrylamide gels with 1
mm thickness in electrophoresis chambers, according to the method described by
Laemmli [159]. We used a lysate from Caco-2 (colon carcinoma cell line) as a
standard reference for Nox1 and a lysate of A7r5 (VSMC line) cell for Nox4. Then,
these chambers were supplied with constant current 15 mA / gel.
5.6.4. Western blotting
Materials:
Blotting buffer (pH10.0)
48 mM               Tris, HCl
39 mM               Glycin
0.1% (w/v)         SDS
20% (v/v)           Methanol
T-TBS (pH 7.5)
20 mM               Tris, HCl
150 mM              NaCl
0.1 % (v/v)         Tween 20
Procedure
Anti-Nox1 and anti-Nox4 rabbit polyclonal antibodies were raised against the
following peptides: Nox1 (aa545561)= RYSSLDPRKVQFYC; Nox4
(aa84101)=RGSQKVPSRRTRRLLDKS; Anti-Nox2 from (Upstate, biotechnology,
Biomol, Hamburg)).
Equal amounts of protein (50 µg) were electrophoretically size separated on 9%
SDS-polyacrylamide gel according to the method described by Laemmli et al. (1970)
[159]. Proteins were transferred into nitrocellulose membranes by semidry blotting at
1.2 mA/cm-2 for 1 h by using blotting buffer as decided by Darley et al. (1992) [160].
Equal rates of transfer were confirmed by reversible staining with Ponceau-S (0.1%
5. Methods
36
(w/v). Non-specific binding was blocked by incubation in 2% non-fat dry milk powder
in T-TBS (see above) at room temperature for 3h.
For Nox1, Nox2 and Nox4 detection in tissue homogenates, anti-Nox1, anti-Nox2
and anti-Nox4 antibodies were diluted in 2% milk with T-TBS and incubated with
nitrocellulose membrane at 4°C overnight. Membranes were washed in T-TBS 4
times for 10 min each. Subsequently, these membranes were incubated for 1 h at
room temperature in dark with the horseradish peroxidase–conjugated secondary
antibody that was diluted in 2% milk. After washing blots with T-TBS 4 times 10 min
each. Finally, they were incubated for 1 min at room temprature with ECL (enhanced
chemiluminescence Amersham Pharmacia Biotech, Germany) or for 5 min with ECL-
advanced (Amersham Pharmacia Biotech).
Signal Quantification
Protein content was analysed by densitometry using Image Station 440CF (Kodak
Digital Science), and light signals were quantified using the Kodak ID image analysis
software (Scientific Imaging System, Eastman Kodak Company, New Haven, USA).
5.6.5. Determination of 3-nitrotyrosine (3NT) immunoreactivity
3NT immunoreactivity in mouse aortic tissue was determined by Western blot
analysis as previously described for Nox1 and Nox4. The anti-nitrotyrosine antibody
employed was polyclonal generated by Uttenthal et al. (1998) [161] in rabbit.  A
secondary antibody (horseradish peroxidase–conjugated antirabbit), diluted in 3%
milk in T-TBS was used. After incubation with the secondary antibody for 1h,
membranes were washed 4 times with T-TBS (each for 15 min). Immunodetections
were visualized using enhanced chemiluminescence kits as previously described.
5.6.6. Determination of sGC protein expression
Lysis buffer of sGC (Marletta buffer)
25 mM           TEA-HCL pH7.0
1 mM              EDTA pH 8.0
5 mM              DTT
50 mM            NaCl
10% (g/v)       Glycerin
Protease inhibitor (complete EDTA free tablet)
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Procedure
The homogenized tissues (25% w/v) were subjected to lysis using the lysis
buffer (see above) at 4°C and with the aid of a tissue girder fitted with a motor-driven
ground-glass pestle. Homogenates were centrifuged at 12000 x g for 5 min at 4°C to
remove nuclear fragments, and the supernatant was used for determination of
protein concentrations. Equal amounts of protein were separated by SDS-PAGE
(9%), and were determined by Western blot analysis as described previously [162].
For sGCa1 and sGCb1 protein detection in tissue homogenates, polyclonal anti-
sGCa1 and sGCb1, as previously described were used [163]. These antibodies were
diluted with 3 % milk in T-TBS and incubated with nitrocellulose membrane at 4°C
overnight. After 3 washing steps with T-TBS (each 15 min), the membranes were
incubated with the secondary antibody. A secondary antibody, diluted with 3% milk in
T-TBS was used. After incubation with the secondary antibody for 1h at room
temprature, membranes were washed for 4 times with T-TBS (each for 15 min).
Incubation with the secondary antibody and washing occurred at room temperature.
Immunocomplexes were visualized using enhanced chemiluminescence kits as
described above for Nox1 and Nox4.
5.6.7. Determination of eNOS protein expression
Homogenization buffer, pH 7.4
10 mM           HEPES buffer
250 mM         Sucrose
3 mM             EDTA
1 mM             PMSF
Procedure
To determine the eNOS protein expression, the tissue pieces were
homogenized in buffer mentioned above [164] at 4 °C with the aid of a tissue girder
fitted with a motor-driven ground-glass pestle. Equal volume of denaturing buffer
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(rotiload buffer), was added and heated to 80°C for 15 min, following which, the
mixture was centrifuged at 5600 g for 3 min. Equal amounts (50 µg) of proteins were
separated by SDS-PAGE (9%), and subjected to Western blotting analysis as
previously described. For immunodetection of eNOS protein expression, anti-eNOS
monoclonal antibody (Transduction Laboratories) diluted (1: 2500) with 3% milk in T-
TBS as described by Vaziri et al. (2001)[165] was used. Anti-mouse antibody
conjugated to horseradish peroxidase in 3% milk in T-TBS was used as secondary
antibody. Incubation with the secondary antibody and washing was performed at
room temperature. Immunocomplexes were visualized using an enhanced
chemiluminescence kit as described before.
5.6.8. Stripping of blots
Materials:
Stripping-Buffer ( pH 6.8)
2%              SDS
62.5 mM     Tris
100 mM      b-Mercaptoethanol
This is a method used for immunodetection of the same blot by another
primary antibody. The primary and secondary antibodies were removed from the
membrane after incubation with 10 ml stripping buffer and warmed in water bath at
60-70°C for 30 min. Then, the stripping was washed out with T-BST at least 4 times
(each time for 15 min).  Thus, these blots are ready to be used for further
immunodetection.
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5.7. Measurement of NADPH–oxidase activity using lucigenin-
enhanced chemiluminescence method
Materials:
Krebs Buffer (pH 7.4)
118 mM         NaCl,
4.7 mM          KCl,
2.5 mM          CaCl2. 2H2O
1.18 mM        MgSO4.7H2O
1.18 mM        KH2PO4
 24.9 mM       NaHCO3
11 mM           Glucose
0.03 mM        EDTA
NADPH-dependent O2-⋅ production was measured in membrane fractions of
mouse aortic homogenates using lucigenin-enhanced chemiluminescence in
concentration of (5 mM) as previously validated [166] to avoid redox cycling. Firstly,
the thoracic aorta was excised, freed from loose connective tissue, minced under
liquid nitrogen and collected in 0.5 ml of 50 mM Tris buffer containing protease
inhibitor cocktail tablets (Roche, Germany) and DTT (10 mM). Membrane fractions
were obtained by differential centrifugation at 500 x g (5 min, 4 °C) and 68000 x g (90
min, 4°C). The pellet containing mainly membranes and microsomes, was
resuspended in 200 ml of Krebs-buffer, (mentioned above) containing 20 mM HEPES
and the protein content was determined. The assay reaction mixture (100 m l)
containing lucigenin (5 mM) and 50 mg of protein was kept in dark at 37°C for 20 min
for equilibration. Using a 96-well plate, the NADPH oxidase activity, was measured in
the presence of NADPH (100 mM) as substrate. Chemiluminescence signals were
measured using the luminescence reader (Fluoroskan Ascent FL) at intervals of I min
over a period of 5 min and the results expressed as Relative Light Unit (RLU). All
measurements were performed in triplicates. The signals were tested in the absence
and presence of different inhibitors such as the NO synthase inhibitor NG-nitro-L-
arginine methyl ester (L-NAME, 100 mM), NADPH oxidase inhibitor apocynin (100
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mM), a flavoprotein inhibitor DPI (10 mM), xanthine oxidase inhibitor oxypurinol (1
mM) and the O2-⋅ scavenger SOD (250 U/ml), respectively.
5.8. Isolated vascular studies
Procedure
Mice were sacrificed by cervical dislocation and the thoracic aorta was rapidly
isolated as described by Russell and Watts [167]. Vessels were stored at 4°C (for up
to 15 min) before being placed in isolated organ baths (IOA 5306 Isolated Organ
Apparatus, (FMI Föhr Medical Instrument, Seeheim, Germany). Before mounting,
each aorta was freed from excess connective tissue and cut into 3 rings of 2-3 mm in
length. Changes in isometric tension were detected by a force transducer and
recorded via a 6 channels transducer data acquisition system (FMI Föhr Medical
Instrument, Seeheim, Germany). Aortic rings from AT1A
-/-, AT1A
+/+, AT2
-/Y and AT2
+/Y
mice were mounted in individual organ baths containing 5 ml of Krebs buffer
maintained at 37°C and bubbled continuously with 5% carbogen. Vessels were
progressively stretched to the optimal resting tension (0.5 g), and then allowed to
equilibrate for 40 min before addition of drugs. Krebs buffer was changed once every
15 min throughout the experiment, except during the generation of concentration-
response curves. After 40-60 min of equilibration, aortic rings were challenged with a
high–potassium solution (120 mM KCl) to determine whether they were viable.
Subsequently, vessels that demonstrated a contraction response to the high
potassium solution were used for further studies. Then, aortic rings were
precontracted submaximally (60-80 %) with100 nM phenylephrine (PE). Then,
concentration-response curves were generated for the endothelium-dependent dilator
acetylcholine (ACh) (1 nM-10 µM). In separate experiments, concentration-response
curves of ACh were generated in the absence and presence of SOD (250 U/ml) and
apocynin (0.1 mM). The concentration-response curves were also determined for the
NO donor spermine NONOate (1 nM-10 µM).
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5.9. Lung isolation perfusion and ventilation
Procedure
For perfusion and ventilation an open chest mouse lung preparation was used
[168]. A water jacketed chamber (type 839, Hugo Sachs ElektroniK, March-
Hugstetten, Germany) served as an artificial thorax, which allowed for control of
system temperature. Mice were deeply anesthetized intraperitoneally with
pentobarbital sodium heparin (1000 U/kg) by intravenous injection. Animals were
then intubated via a tracheostoma and ventilated with room air (positive pressure
ventilation, 250 tidal volume, 90 breath/min and 2 cm H2O positive end-expiratory
pressure).  Midsternal thoracotomy was followed by insertion of catheters into the
pulmonary artery and left atrium. Using a peristaltic pump (ISM834A V2.10, Ismatec,
Glattbrugg, Switzerland), buffer perfusion via the pulmonary artery was initiated at
4°C and a flow of 0.2 ml/min. For perfusion, a variety of buffer solutions were
investigated. In parallel with the onset of artificial perfusion, ventilation was changed
from room air to a pre-mixed gas (21% O2 5.3% CO2, balanced with N2). After rinsing
the lungs with ≥ 20 ml buffer, the perfusion circuit was closed for recirculation (total
system volume 13 ml) and left arterial pressure was set at 2.0 mmHg. Meanwhile the
flow was slowly increased from 0.2 to 1 ml/min and the entire system heated to 37°C.
Pressure in the pulmonary artery was registered via a small diameter catheter.
During surgery, the lungs were ventilated with positive pressure. After placing the
catheter, the artificial thorax was closed and the lungs were ventilated with negative
pressure. For inspiration, negative pressure was adjusted to result in a tidal volume
of ~ 250 ml. End-expiratory pressure was held constant at –2 cm H2O.
Statistical analysis
All experiments were performed in parallel on preparations from knockout and
wild-type mice. Results are expressed as mean ± SEM. Statistical evaluation of the
data was performed by unpaired Student´s t test for simple comparison between 2
values when appropriate. For multiple comparisons, results were analyzed by
ANOVA and tested with Bonferonni multiple range tests. EC50 values were calculated
with a non-linear regression analysis with algorithm. A value of P < 0.05 was
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considered significant. All statistical evaluations were performed using Graphpad
prism software (San Diego, CA, USA).
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6. Results
6.1. Effect of the targeted deletion of AT1A or AT2 receptors on
expressions of Nox1 and Nox4
In the present study, it was of interest to recognize the effect of Ang II
receptors (AT1A and AT2) on the expressional regulation of Nox1, Nox2 and Nox4
under physiological conditions using animals that are genetically deficient in Ang II
receptors (AT1A or AT2). Western blotting revealed that the expression of NADPH
oxidase subunits (Nox1 and Nox4) was significantly reduced in aortic tissues of AT1A
-
/- mice when compared with AT1A
+/+ mice. As shown in Fig. 6.1., Nox1 expression
level was dramatically decreased to the one-fifth of that in AT1A
+/+ mice (20.6 ± 9.3%
of AT1A
+/+ mice, ** P < 0.01), and Nox4 level was diminished to the one-half of that in
AT1A
+/+ mice (49.6 ± 6.8% of AT1A
+/+ mice, * P < 0.05) (Fig. 6.2.).
Fig. 6.1. Nox1 expression in aortic homogenates of AT1A
-/- and AT1A
+/+ mice. A.
Representative immunoblot of Nox1 expression in aortic homogenates of AT1A
-
/- and AT1A
+/+ mice. B. Densitometric analysis of Nox1 immunoblot in aorta of
AT1A
-/- mice. Values are normalized to the level seen in AT1A
+/+ mice (100%). In
AT1A
-/- mice, the aortic Nox1 expression level was significantly downregulated
compared to that in AT1A
+/+ mice. Values represent means ± SEM of n = 6
experiments. Asterisks indicate statistically significant differences   (** P <
0.01; Student ’s unpaired t-test).
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Fig. 6.2. Nox4 protein expression in aortic tissues of AT1A
+/+ and AT1A
-/- mice. A.
Representative immunoblot of Nox4 expression in aortic homogenates of AT1A
-
/- and AT1A
+/+ mice. B. Densitometric analysis of Nox4 immunoblot in aorta from
AT1A
-/- mice. Values are expressed as % of AT1A
+/+ mice. Data show a significant
decrease in Nox4 expression in aortic tissues from AT1A
-/- mice versus that in
AT1A
+/+ mice. Values represent means ± SEM of n=6 experiments (** P < 0.01;
Student ’s unpaired t-test).
 Although in vitro regulation of NADPH oxidase subunits by AT2 receptor has been
recently reported [141], there is a lack of information regarding in vivo regulation of
this oxidase by AT2 receptor. In the present work, we tried to evaluate the regulatory
role of AT2 receptor on the protein expression of Nox1 and Nox4 under physiological
conditions using AT2 receptor-deficient mice. Surprisingly, targeted disruption of the
AT2 receptor did not significantly alter the aortic Nox4 expression level versus that in
AT2
+/Y mice (Fig. 6.3.). However, in the aorta from AT2
-/Y mice, Nox1 expression level
was downregulated to the two-third of that in AT2
+/Y mice (68.4 ± 4.1 % of AT2
+/Y
mice, * P < 0.05). On the other hand, Nox2 protein expression exhibit no significant
difference in aortic tissues of either AT1A
-/- or AT2
-/Y mice in comparison to their
respective wt.
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Fig. 6.3. Nox4 protein expression in aortic tissues of AT2
-/Y and AT2
+/Y mice. A.
Representative immunoblot of Nox4 expression in aortic homogenates of AT2
-/Y
and AT2
+/Y mice. B. Densitometric analysis of Nox4 immunoblot in aortic
homogenates of AT2
-/Y, expressed as % of AT2
+/Y mice. Values represent means
± SEM of n = 6 experiments. Data show no significant differences in Nox4
expression levels between aortic tissues from AT2
-/Y and AT2
+/Y mice.
Due to the importance of NADPH oxidase-derived ROS in the lung function
and signaling events in the pulmonary artery [92, 169], regulation of Nox1 and Nox4
expression in lung homogenates of AT1A
-/- and AT2 
-/Y mice was investigated.  In the
lung of AT1A
-/- mice, Nox1 expression was mildly decreased compared to that in
AT1A
+/+ mice (61.1 ± 6.2% of AT1A
+/+ mice, P < 0.05), Nox4 expression level remained
unchanged. In the lung of AT2
-/Y mice, Nox1 expression level was significantly
upregulated (129.4 ± 14,2% of AT2
+/Y mice, * P < 0.05)(data not shown). In addition,
the lung of AT2
-/Y mice revealed a dramatic increase in the Nox4 expression with
respect to that of AT2
+/Y mice. We found that Nox4 expression level was
approximately 4.7-fold higher (476 ± 85.8% of AT2
+/Y mice. ** P < 0.001) than that in
AT2
+/Y mice (Fig. 6.4.).
6. Results
46
Fig. 6.4. Nox4 expression in the lung homogenates of AT2
+/Y and AT2
-/Y mice.  A.
Representative immunoblot of Nox4 expression in the lung homogenates of
AT2
-/Y and AT2
+/Y mice.  B. Densitometric analysis of Nox4 immunoblot in the
lung of AT2
-/Y mice, expressed as % of the AT2
+/Y mice. Nox4 expression level
was 4.7-fold greater than that in AT2
+/Y mice. Data represent means ± SEM of n =
5 experiments (** P < 0.01; Student ’s unpaired t-test).
6.2. Effect of the targeted deletion of AT1A or AT2 receptors on
NADPH oxidase activity
In order to examine the NADPH oxidase expression-functional correlation,
NADPH oxidase activity was measured in aortic membrane fractions from AT1A
-/- and
AT1A
+/+ mice using lucigenin-enhanced chemiluminescence method [166]. As shown
in Fig. 6.5., addition of NADPH (100 mM) as a substrate resulted in a substantially
stimulation of O2 -⋅ production in aortic homogenates of AT1A
-/- and AT1A
+/+ mice.
However, addition of 100 mM of NADH had no stimulatory effect, suggesting an
NADPH oxidase and no non-specific NADH oxidoreductase component was
involved.
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Fig. 6.5. Basal NADPH-dependent O2-⋅ generation in aortic homogenates of
AT1A
-/- and AT1A
+/+ mice in the absence and presence of NADPH and NADH as a
substrate, estimated using lucigenin-enhanced chemiluminescence method.
NADPH rather than NADH oxidase is mainly involved in the lucigenin-enhanced
chemiluminescence. In the aorta of AT1A
-/- mice, the level of lucigenin
chemiluminescence was markedly decreased compared to that in AT1A
+/+ mice.
ROS levels are expressed as relative light units (RLU). Data represent means ±
SEM of 7 independent experiments (** P < 0.01, AT1A
+/+ versus that in AT1A
-/-
mice; ANOVA-test).
In addition, in aortic homogenates of AT1
-/- mice, we have found that NADPH-
dependent O2-⋅ production was significantly lower than that in AT1A
+/+ mice  (39.8 ± 4
in AT1A
-/- mice versus 70.8 ± 6 in AT1A
+/+ mice; **P < 0.01 RLU/min). To distinguish
the NADPH-dependent O2-⋅ formation from other O2-⋅-generating enzymes such as
xanthine oxidase and uncoupled eNOS, the basal O2-⋅ formation was measured in
the absence and presence of respective inhibitors of these enzymes. Neither the
xanthine oxidase inhibitor (oxypurinol) nor the NOS inhibitor (L-NAME) was able to
produce significant effects on basal O2-⋅ formation. However, the enhanced
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chemiluminescence signals were abolished by the flavoprotein inhibitor DPI (10 mM),
and inhibited to 50% by apocynin. The specificity of the specificity of lucigenin
chemiluminescence for O2-⋅ quantification was examined by the effect of SOD (O2-⋅
scavenger) that was additionally determined. We observed that SOD inhibited
approximately about 64% of the lucigenin chemiluminescence level (Fig. 6.6.).
Fig. 6.6. Effect of different inhibitors of O2-⋅-generating enzymes on the NADPH-
dependent O2-⋅ production in aortic homogenates of AT1A
-/- and AT1A
+/+ mice.
The level of lucigenin chemiluminescence signals in aortic homogenates of
AT1A
-/- and AT1A
+/+ mice were measured in the absence and presence of
different inhibitors to O2-⋅-generating enzymes. Values represent means ± SEM
of 7 independent experiments (** P < 0.01, *** P < 0.001 for AT1A
+/+ versus AT1A
-/-
mice; ANOVA-test).
Fig. 6.7. illustrates our calculation of the absolute inhibitable ROS formation
for apocynin, SOD and DPI based on the data shown in Fig. 6.6.  It is noteworthy that
the absolute inhibitable ROS generation by apocynin and DPI in aortic tissues from
AT1A
+/+ mice (exclusively represent NADPH oxidase activity) were 1.4 and 1.8 -fold,
respectively greater than that in AT1A
-/- mice. The inhibitable effect of ROS by SOD
indicates the specificity of the chemiluminescence signals to superoxide anions.
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Fig. 6.7. A/B Calculation of the data from Fig. 6.6., A. Absolute values of ROS
inhibitable formation for apocynin, SOD and  DPI in aortic tissues of AT1A
+/+ and
AT1A
-/- mice. B. ROS Inhibitable formation of apocynin, SOD and DPI are
expressed as % of AT1A
+/+ mice. Only the apocynin-inhibitable signal is
considered to represent exclusively NADPH oxidase activity.
Recently, it has been described that AT2 receptor functions as antagonist of the
AT1 receptor-induced O2 -⋅ formation in endothelial cells by a tyrosine phosphatase
involved pathway [170]. Nevertheless, nothing is known regarding the role of AT2
receptors in basal O2 -⋅ formation. To analyse the possible role of the AT2 receptor in
basal activity of NADPH oxidase, we have studied NADPH oxidase-dependent O2-⋅
production in aortic homogenates from AT2
+/Y and AT2
-/Y mice. Surprisingly, we found
that aortic homogenates from AT2
-/Y mice showed insignificant differences in basal
NADPH oxidase activity compared to that in AT2
+/Y mice. In addition, absolute
inhibitable chemiluminescence signals for apocynin in membrane fractions from AT2
+/Y
and AT2
-/Y mice were similar (Fig. 6.8.).
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Fig. 6.8. The basal O2-⋅ formation in aortic homogenates of AT2
-/Y and AT2
+/Y
mice, detected by lucigenin-enhanced chemiluminescence method. ROS
production was determined in the absence and presence of different inhibitors
to O2-⋅-generating enzymes in aortic membrane fractions of AT2
-/Y and AT2
+/Y
mice. ROS levels are reported as RLU. Values represent means of RLU ± SEM
of 7 experiments (** P < 0.01, *** P < 0.001 indicate significant differences
between AT2
-/Y and AT2
+/Y mice in the absence and presence apocynin and DPI,
respectively; ANOVA-test).
6.3. Targeted deletion of AT1A receptors and nitrosative stress
The interaction between endothelium-derived NO and O2 -⋅
 may lead to highly
reactive intermediates such as peroxynitrite (ONOO --) [171]. Protein tyrosine nitration
(3NT) and increased vasoconstrictor tone are biochemical and functional indicators
of the so-called endothelial dysfunction. To examine whether the alteration in Nox1
and Nox4 expression levels was reflected in the protein nitration in vascular tissues,
3NT immunoreactivity was assessed in aortic homogenates of AT1A
-/- mice with
respect to their wt mice. Interestingly, in aorta of AT1A
-/- mice, the reduced expression
level in Nox1 and Nox4 was associated with a subsequent decrease in 3NT contents
compared to that in AT1A
+/+ mice (44.5 ± 7.3% of AT1A
+/+ mice, * P < 0.05) (Fig. 6.9.).
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Fig. 6.9. Nitrotyrosine immunoreactivity in aortic homogenates of AT1A
+/+ and
AT1A
-/-mice. A single immunoreactive band was detected in protein extract from aortic
homogenates of AT1A
-/- and AT1A
+/+ mice. A. Representative immunoblot of the 3NT
abundance in aortic homogenates of AT1A
-/- and AT1A
+/+ mice.  B. Densitometric
analysis of 3NT immunoblot in aorta of AT1A
-/- mice, expressed as % of the AT1A
+/+ mice,
demonstrating that 3NT immunoreactivity was markedly reduced in aorta of AT1A
-/-
mice versus AT1A
+/+. Data represent means ± SEM of n=5 experiments (* P < 0.05;
Student ’s unpaired t-test).
6.4. Effect of the targeted deletion of AT1A or AT2 receptors on the
expression levels of eNOS
Several studies have demonstrated the importance of the aortic Ang II
receptors-bradykinin-NO-cGMP vasodilator cascade under normal conditions [172].
Previously, Ang II has been found to stimulate an increase in cellular NO level or
cGMP content in mouse aorta via activation of AT2 receptors [19]. However, a
potential contribution of AT1 receptors to Ang II-aortic cGMP signaling has been
recently suggested [172].  In the present study, we examined the specific Ang II
receptor subtypes AT1A and AT2 that may contribute to regulation of eNOS
expression (as a target for the NO-cGMP pathway) under physiological conditions.
Western blot analysis showed that aortic homogenates of AT2
-/Y mice exhibited a
significant decrease in the eNOS expression level to the one-half of that in AT2
+/Y
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mice (Fig. 6.10.). However, aortic tissues of AT1A
-/- mice showed insignificant
changes in eNOS expression compared to that in AT1A
 +/+ mice (Fig. 6.11.).
Fig. 6.10. Expression of eNOS in aortic homogenates of AT2
-/Y and AT2
+/Y mice.
A. Representative immunoblot of eNOS expression in the aorta from AT2
-/Y and
AT2
+/Y mice. B. Quantitative densitometry analysis of eNOS expression in aorta
of AT2
-/Y mice, expressed as % of AT2
+/Y mice. As shown, in the aorta of AT2
 -/Y
mice, eNOS expression was significantly decreased to the one-half of that in
AT2
+/Y (52.8 ± 3.2% of wt). Data represent means ± SEM of 4 experiments (* P <
0.05; Student ’s unpaired t-test).
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Fig. 6.11. Expression of eNOS in aortic homogenates of AT1A
+/+ and AT1A
-/- mice.
A. Representative immunoblot of eNOS expression in the aorta from AT1A
-/- and
AT1A
+/+ mice. B. Quantitative densitometry analysis of eNOS expression in the
aorta of AT1A
-/- mice, expressed as % of AT2
+/Y mice. Data represent means ±
SEM of 4 experiments. As shown, the aorta of AT1A
-/- mice exerted insignificant
differences in eNOS expression compared to that in AT1A
+/+ mice.
In the lung of AT2
-/Y mice, Western blotting analysis revealed that eNOS expression
level was significantly downregulated to 50.4 ± 2.5% of that in AT2
+/Y mice (P <
0.01)(Fig. 6.12.).
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Fig. 6.12. Expression of eNOS in lung homogenates of AT2
-/Y and AT2 
+/Y mice.
A. Representative immunoblot of eNOS expression in the lung of AT2
-/Y and
AT2
+/Y mice. B. Quantitative densitometry analysis of eNOS expression in the
aorta of AT2
-/Y mice, expressed as % of AT2
+/Y mice. As shown, in the lung of
AT2
-/Y mice, eNOS expression level was markedly decreased to the one-half of
that in AT2
+/Ymice. Data represent means ± SEM of 5 experiments (** P < 0.01;
Student ’s unpaired t-test).
6.5. Effect of the targeted disruption of AT1A or AT2 receptors on the
expression of sGC subunits (a1 and b1)
sGC is expressed in the cytoplasm of almost all mammalian cells. This
heterodimeric enzyme consists of a and b subunits, and both are required for the
catalytic activity. Structural analysis of sGC in different tissues indicates multiple
isotypes with different subunit compositions. In blood vessels, the most abundant
subunits are a1 and b1.
In the present study,we tried to characterize the molecular regulation of sGC by AT1A
and AT2 receptors under basal conditions using mice deficient in AT1A or AT2
receptors as appropriate approach for this. In the aorta from AT1A
-/- mice, Western
blotting data revealed that gene-targeted deletion of the AT1A receptors did not
significantly alter the expression level of either sGCa1 (Fig. 6.13.) or b1 (Fig. 6.14.)
subunit compared to that in AT1A
+/+ mice.
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Fig. 6.13. Expression of sGCa1 subunit in aortic homogenates of AT1A
-/- and
AT1A
+/+ mice. A. Representative immunoblot of the sGCa1 expression in aortic
homogenates of AT1A
-/- and AT1A
+/+ mice. B. Densitometric analysis of sGCa1
immunoblot in aorta from AT1A
-/- mice, expressed as % of AT1A
+/+ mice. As
shown, in the aorta of AT1A
-/- mice, sGCa1 expression level did not significantly
differ from that in AT1A
+/+ mice. Data represent means ± SEM of n=5
experiments.
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Fig. 6.14. Expression of sGCb1 subunit in aortic homogenates of AT1A
-/- and
AT1A
+/+ mice. A. Representative immunoblot of sGCb1 expression in aortic
homogenates of AT1A
-/- and AT1A
+/+ mice. B. Densitometric analysis of the sGCb1
immunoblot in aorta of AT1A
-/- mice, expressed as % of AT1A
+/+ mice. As shown,
the sGCb1 expression was not significantly different from that in AT1A
+/+ mice.
Data represent means ± SEM of n=5 experiments.
It is noteworthy that in aortic homogenates of AT2
-/Y mice, the expression levels of
sGC (a1 and b1) were markedly lower than that in AT2
+/Y mice (60.3 ± 8.7% and 62.3
± 4.8 % of AT2
+/Y mice, respectively) (Fig. 6.15.).
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Fig. 6.15.  Expression of sGC subunits (a1 and b1) in aortic homogenates of
AT2
-/Y and AT2
+/Y mice. A. & C. Representative immunoblots of sGCa1 and b1
subunits, respectively in aortic homogenates of AT2
-/Y and AT2
+/Y mice. B. & D.
Summarized data for quantitative densitometry analysis of sGCa1 and b 1
expression, respectively in aortic homogenates of AT2
-/Y mice are expressed as
% of AT2
+/Y mice. In the aorta from AT2
-/Y mice results demonstrate a significant
reduction in the expression of sGCa1 and b1 subunits by about 40% and 38%,
respectively compared to that in AT2
+/Y mice. Data represent means ± SEM of 5
experiments; at * P < 0.05 and ** P < 0.01 (Student ’s unpaired t-test).
In addition, we have also investigated the protein expression of sGC subunits (a1 and
b1) in the lung of AT2
-/Y mice. The most important observation was the dramatic
reduction in the sGCb1 subunit expression nearly to the one-third of that in AT2
+/Y
mice (32.8 ± 5.3% AT2
+/Y mice, *** P < 0.001)(Fig. 6.16.), whereas the sGCa1 subunit
protein expression was decreased to a lesser extent.
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Fig. 6.16. Expression of sGCb1 subunit in lung homogenates of AT2
 -/Y and
AT2
+/Y mice. A. Representative immunoblot of sGCb1 expression in lung
homogenates of AT2
-/Y and AT2
+/Y mice. B. Quantitative densitometry of the
sGCb1 expression level in the lung from AT2
-/Y mice, expressed as % of AT2
+/Y
mice. Results show a significant reduction of sGC b1 expression level in the
lung from AT2
-/Y mice versus that in AT2
+/Y mice. Data represent means ± SEM
of 4 experiments (*** P < 0.001; Student ’s unpaired t-test).
6.6. Effect of the targeted deletion of AT1A and AT2 receptors on
vascular functions
To examine the functional significance of the decreased NADPH oxidase
activity in the aorta of AT1A
-/- mice, the endothelium-dependent and independent NO-
mediated vasodilatory effects were studied. Using PE-preconstricted aortic rings from
AT1A
-/- and AT1A
+/+ mice, we could observe that the maximal response (Emax) of ACh-
induced endothelium dependent relaxation was significantly enhanced in the aortic
rings from AT1A 
-/- mice versus that in AT1A
+/+ mice (Emax in AT1A
+/+ mice= 55.4 ± 4.1
versus 73.3 ± 5.9 in AT1A
-/- mice, * P < 0.05).
To understand the mechanism(s) behind the differential relaxation, responses to ACh
were studied in the absence and presence of apocynin (NADPH oxidase inhibitor) or
6. Results
59
SOD (superoxide anion scavenger). The difference in Emax of ACh-induced relaxation
in aortic rings from AT1A
-/- and AT1A
+/+ mice was abolished after incubation with
apocynin (0.1 mM) (Fig. 6.17.), or SOD (250 U/ml) (Fig. 6.18.).
 
Fig. 6.17. Effect of ACh-mediated mediated endotheium-dependent relaxation
on aortic rings in PE-preconstricted aortic rings from AT1A
+/+ versus AT1A
-/- mice
in the absence and presence of apocynin (0.1 mM). Concentration-response
curves showing relaxation responses to ACh in PE-preconstricted aortic rings
from AT1A 
+/+ versus AT1A 
-/- mice as well as the effect of pretreatment with
apocynin.  Each point is the mean ± SEM of 7 independent experiments. * P <
0.05 indicates significant differences in Emax of ACh-induced relaxation in aortic
rings from AT1A
-/- mice compared to that in AT1A
+/+ mice, and # P  < 0.05
indicates significant differences in Emax of ACh-induced relaxation in aortic
rings from AT1A
+/+ mice before and after treatment with apocynin; ANOVA and
Bonferroni ’s multiple comparison test.
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Fig. 6.18. Effect of ACh-mediated endotheium-dependent relaxation on aortic
rings in PE-preconstricted aortic rings from AT1A
+/+ versus AT1A
-/- mice in the
absence and presence of SOD (250 U/ml). Concentration-response curves
showing relaxation responses to ACh in PE-preconstricted aortic rings from
AT1A
+/+ versus AT1A
-/- mice as well as the effect of pretreatment with SOD. Each
point is the mean ± SEM of 8 independent experiments. * P < 0.05 indicates
significant differences in Emax of ACh-induced relaxation in aortic rings from
AT1A
-/- mice compared to the AT1A
+/+ mice, and # P < 0.05 indicates significant
differences in Emax of ACh-induced relaxation in aortic rings from AT1A 
+/+ mice
before and after treatment with SOD; ANOVA and Bonferroni ’s multiple
comparison test.
In aortic rings from AT1A
-/- mice, however, spermine NONOate-mediated
endothelium-independent vasodilatation did not significantly differ from that of AT1A
+/+
mice (Fig. 6.19.).
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Fig. 6.19. Concentration-response curves of spermine NONOate-induced
endothelium-independent relaxation in PE-preconstricted aortic rings of AT1A
+/+
and AT1A
-/- mice. As shown, the relaxation responses in aortic rings of AT1A
-/-
mice did not significantly differ from that of AT1A
+/+ mice.  Each point is the
mean ± SEM of 6 independent experiments.
On the other hand, the role of AT2 receptors in the regulation of vascular tone was
analysed in several studies [14, 18, 173]. However, the underlying signaling
mechanism of AT2 receptors-mediated vasodilatation under physiological condition is
not clearly defined. Accordingly, the present study was designed to investigate the
relaxation responses to ACh (endothelium-dependent vasodilator) and the NO donor,
sermine NONOate (endothelium-independent vasodilator) in PE-preconstricted aortic
rings from AT2
-/Y mice. In comparison to aortic rings of AT2
+/Y mice, we observed a
significant reduced sensitivity (affinity) to ACh as well as spermine NONOate-induced
relaxations in aortic rings of AT2
-/Y mice. This was evidenced by a significant increase
in pD2 (-log EC50) value of ACh-mediated relaxation response curves pD2; 7.28 ±
0.06 in AT2
-/Y mice versus 7.68 ± 0.04 in AT2
+/Y mice; *** P < 0.001) (Fig. 6.20) and
pD2 value of spermine NONOate (pD2; 6.74 ± 0.06 in AT2
-/Y mice versus 7.16 ± 0.04
in AT2
+/Y mice; ** P < 0.01)(Fig. 6.21).
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Fig. 6.20. Concentration-response curves of ACh-mediated endothelium-
dependent relaxation in aortic rings of AT2
+/Y and AT2
 -/Y mice. Results show a
significant rightward shift of ACh concentration response curve in aortic rings
from AT2
-/Y mice compared to that in AT2
+/Y mice (pD2; 7.28 ± 0.06 in AT2
-/Y
versus 7.68 ± 0.04 in AT2
+/Y mice, *** P < 0.001). Each point is the mean ± SEM
of 7 independent   experiments.
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Fig. 6.21. Concentration-response curves of endothelium-independent
relaxation to spermine NONOate on PE-preconstricted aortic rings from AT2
+/Y
and AT2
 -/Y mice. Results show a significant rightward shift of spermine
NONOate concentration response curve in aortic rings of AT2
-/Y mice compared
to that in AT2
+/Y mice (pD2; 6.74 ± 0.06 in AT2
-/Y mice versus 7.16 ± 0.04 in AT2
+/Y
mice; ** P  < 0.01). Each point is the mean ±  SEM of 7 independent
experiments.
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Concerning the functional data in the lung of AT2
-/Y mice, we have found that
the basal arterial pulmonary pressure was significantly higher than that of AT2
+/Y mice
(6.7 ± 0.2 in AT2
+/Y mice versus 7.7 ± 0.13 in AT2
-/Y mice mmHg, P < 0.13, n = 4
experiments)(Fig.  6.22.).
Fig. 6.22. The basal pulmonary artery pressure in the isolated buffer-perfused
and ventilated lung of AT2
-/Y and AT2
+/Y mice. The baseline Pulmonary artery
pressure was markedly increased in AT2
-/Y mice versus AT2
+/Y mice. Data
represent means ± SEM of 4 independent experiments; at P < 0. 13 (Student ’s
unpaired t-test).
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7. Discussion
7.1. Nox1 and Nox4 expression in AT1A
-/- and AT2
-/Y mice
Ang II plays an important role in regulating cardiovascular functions in health
and disease. So far, most of the actions induced by Ang II are attributed to the AT1
receptors, because AT1 receptors expression seems to be necessary for these
effects. For example, AT1 receptors are downregulated by Ang II and growth factors
diminishing the effects of Ang II on intracellular signaling [174-176]. In mouse and rat,
two subtypes of the AT1 receptor, AT1A and AT1B have been identified [3]. An
increasing body of evidence supports the hypothesis that the AT1A receptors are
responsible for most of the physiological actions of Ang II. In particular, AT1A
receptors are much more expressed in vasculature and cardiac tissues than AT1B
receptors [177, 178]. The AT1A
-/- mouse model was originally developed by Coffman
et al. (1995) [26] and has been previously used to examine putative differences in the
function of AT1A and AT1B receptors [179].  These mice have lower blood pressure
compared to that in wt littermates, and the pressor response to Ang II infusion was
absent [26]. In addition, gene-targeting of the AT1A receptor results in alteration in
renal function and salt sensitivity [180]. In contrast, AT1B receptor-deficient mice have
normal basal blood pressure and only a few phenotypic changes have been
observed [28]. Thus, the comparison between both knockout models supports the
hypothesis that the AT1A receptor plays the primary role in regulation of renal and
cardiovascular functions.
It is currently well established that Ang II induces intracellular formation of
ROS in the vasculature and NADPH oxidase system is a major source for Ang II
induced ROS production. A number of Nox homologise including Nox1, 4, and 2,
have been identified in vascular cells [87, 101, 181], with endothelial cells expressing
very low levels of Nox1, intermediate levels of Nox2, and abundant Nox4 mRNA [83,
181]. In contrast, VSMCs express predominantly Nox4 [87, 99] and to a lesser extent
Nox1 [87, 101], with negligible amounts of Nox2. NADPH oxidase-mediated O2-⋅
production is increased in vessels of rabbits with experimental atherosclerosis [120].
These abnormalities were corrected by AT1 receptor blockade [120]. Further, it was
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demonstrated that losartan treatment decreases the p22phox mRNA expression and
NADPH oxidase activity in cultured VSMCs stimulated by Ang II [137, 143]. Thus,
AT1 receptor seems to predominately contribute to O2-⋅ production via NADPH
oxidase in vasculature. Studies examining vascular expression of NADPH oxidase
subunits revealed that Ang II infusion upregulates Nox1 and Nox4 mRNA expression
levels in rat aorta [57]. Previously, our group has shown that Nox4 mRNA expression
was significantly increased in rats made hypertensive by overexpression of the
human renin gene [87] or infusion of Ang II for 7 days [57]. Although several studies
have shown that Ang II increases the generation of O2-⋅ in cultured endothelial [182,
183] and VSMCs  [89], there is a disagreement regarding the receptor subtypes (AT1
or AT2) involved in NADPH oxidase-mediated O2-⋅ production in vitro [182, 183].
Moreover, which of the Nox isoforms functionally couple to Ang II receptors under
physiological conditions is not known. Thus, identification of the protein regulation of
these NADPH oxidase isoforms by Ang II receptors (AT1A and AT2) under
physiological conditions is a prerequisite to target specific cellular events contributing
to a pathological state. We herewith show using AT1A receptor gene targeting mice,
that aortic tissues of AT1A
-/- mice exhibited a marked downregulation of Nox1 and
Nox4 expression versus that of AT1A
+/+ mice. These findings support in vivo findings
regarding the involvement of the supraphysiological levels of Ang II [87] [57] in
regulation of Nox1 and Nox4. Our present data also confirm our previous in vitro
results concerning the involvement of Ang II in regulating Nox1 and Nox4 mRNA
levels in VSMCs [87].
Several studies provide evidence that Ang II receptors differentially modulate
endothelial superoxide anion formation. While AT1 receptor activates O2-⋅ formation,
AT2 receptor attenuates this AT1 receptor-induced effect [183]. Recently,
Rueckschloss et al. (2002) [141] have shown a dose-dependent regulation of
endothelial NADPH oxidase by Ang II. They have observed that induction of
gp91phox expression is mediated by AT1 receptors, whereas AT2 receptors
stimulation causes its partial inhibition [141]. In Ang II-infused rat kidney, it has been
shown that AT1 receptor antagonists decrease mRNA expression levels of both
p22phox and Nox1 [184], whereas blockade of AT2 receptors intensifies the effect of
Ang II-induced increase in mRNA expression of these subunits, suggesting a
countervailing effect of AT1 and AT2 receptors [184]. Nevertheless, the potential role
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of AT2 receptor in expressional regulation of NADPH oxidase under physiological
conditions remains to be clarified. To our surprise, in aorta of AT2
-/Y mice, although
Nox1 expression exhibited a significant reduction, Nox4 expression remained
unchanged compared to that in AT2
+/Y mice. To confirm this observation, we
measured the activity of the NADPH oxidase in the aorta of these animals.
On the other hand, the importance of NADPH oxidase-derived ROS in lung
function and signaling events of the pulmonary arterial smooth muscle cells has been
reported in several studies [92, 169, 185]. Recently, it has been suggested that
among these oxidases, Nox4 plays an important role not only in mitogenesis of these
cells, but also in oxygen sensing [186]. Furthermore, it has been demonstrated that
Ang II receptors (AT1 and AT2) have a potential role in modulation of the pulmonary
vascular tone [187]. The current study provides evidence for a molecular regulation
of Nox4 by AT1A and AT2 receptors. In the lung from AT2
-/Y mice, we observed that
Nox4 expression level exhibited was dramatically upregulated compared to that in
AT2
+/Y animals. However, the lung of AT1A
-/- mice could not show significant
differences in the expression level of Nox4 compared to that in AT1A
+/+ mice. These
findings suggest that AT2 receptors rather than AT1 receptors probably contribute to
regulation of Nox4 protein expression in the lung.
7.2. Effect of the targeted deletion of AT1A or AT2 receptors on the
NADPH activity
Previously, it has been shown that NADPH oxidase is involved in vascular O2-⋅
generation under normal conditions [92], and it is well known that Ang II activates
NADPH oxidase in the vasculature [89, 136]. NADPH oxidase–mediated O2-⋅
production was increased in vessels of rabbits with experimental atherosclerosis
[120]. These abnormalities were corrected by AT1 receptors blockade [120].
However, it has been recently shown that both of the Ang II receptors (AT1 and AT2)
could induce NADPH oxidase-dependent O2-⋅ formation [188]. Thus, it was necessary
to identify the Ang II receptor subtypes that might predominantly contribute to the
NADPH oxidase activity under physiological conditions. In addition, to examine
whether the regulation of Nox1 and Nox4 by endogenous Ang II was limited to its
expression or was also involved with its activity, we measured basal ROS production
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by lucigenin-enhanced chemiluminescence in aortic homogenates from AT1A
-/- and
AT2
-/Y mice.
Validation of lucigenin experiments
Majority of data, regarding O2-⋅ formation in vessel homogenates, are based
on the measurement of the intensity of lucigenin-enhanced chemiluminescence [136,
189]. The validity of these data was recently questioned, because lucigenin at high
concentrations itself increases formation of O2-⋅ in the presence of flavin-containing
enzymes such as NO synthase and xanthine oxidase [65, 190] that are capable of
providing one-electron reduction of lucigenin. Hence, to avoid false-positive signals
or redox cycling, we performed our experiments using low concentrations of lucigenin
(5 mM) [191]. In our experiments, we used the particulate fractions that contain mainly
membranes and microsomes [136].
Concurrent to our expression data in the aorta of AT1A
-/- mice, the basal
NADPH oxidase activity was significantly lower in aorta of AT1A
-/- mice versus AT1A
+/+,
indicating that aorta of AT1A
-/- mice contains less active, membrane-associated
NADPH oxidase compared to that in AT1A
+/+ mice. The signal was completely blocked
by DPI (non-specific flavin binding NADPH oxidase inhibitor), and partially blocked by
apocynin (more specific NADPH oxidase inhibitor). Of particular interest, the absolute
apocynin inhibitable signal (which exclusively represents the Nox activity) was higher
in AT1A
+/+ mice compared to AT1A
-/- mice. This signal was unaffected by inhibitors of
other potential O2-⋅-generating enzymes, such as L-NAME (uncoupled NOS) or
oxypurinol (xanthine oxidase). The lack of effects of L-NAME and oxypurinol
suggests that the uncoupled-eNOS or xanthine oxidase enzyme, respectively were
not involved in the difference of the basal O2-⋅ formation in aorta from AT1A
+/+ versus
AT1A 
-/- mice. Supporting this, we did not any significant alterations in the eNOS
expression levels in aorta from AT1A
-/- mice compared to that in AT1A
+/+ mice. Based
on these observations, we propose that NADPH oxidase enzyme is responsible for
the majority of basal O2-⋅ formation, which can be mediated via AT1A receptor.
Further, in the absence of substrate (NADPH) or when NADPH was substituted with
NADH, the O2-⋅ production was undetectable. The observation of enhanced O2-⋅
production in mouse aortic homogenates on supplementation with NADPH and not
NADH, suggests that in our hands the enzyme in aortic homogenate seems to be
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NADPH oxidase and not NADH oxidase as reported by some groups [191, 192].
Together, these findings are in a good agreement with a very recent study [179],
supporting the activation of AT1A receptor being associated with oxidative stress in
the mouse vasculature. These results support previous reports, showing that AT1
receptor antagonists block the Ang II-induced O2-⋅ formation in endothelial cells [182,
193], VSMCs [89], and intact aortic segments [120, 194]. Overall, these findings
provide an important physiological relevance of AT1A receptors in regulation of the
expression of NADPH oxidase but also its activity.
On the other hand, the role of AT2 receptors in the in vitro regulation of
NADPH oxidase enzyme has been analyzed in several studies [182, 183] [89].
Furthermore, in fibroblasts and endothelial cells, concomitant application of AT2
receptor antagonists further augmented Ang II-induced NADPH oxidase activity [98,
141]. Nevertheless, the physiological relevance of AT2 receptor in NADPH oxidase
activity in vivo under physiological condition is unknown. In addition, it was necessary
to examine whether the reduced expression of Nox1 in aortic tissues of AT2
-/Y mice
can affect on the activity of the oxidase enzyme. Hence, we estimated NADPH-
dependent O2-⋅ formation in aortic homogenates of AT2
-/Y and AT2
+/Y mice.
Surprisingly, gene-targeted deletion of the AT2 receptor resulted in insignificant
alterations in NADPH oxidase activity (as evidence by apocynin inhibitable ROS
formation) in aortic tissues from AT2
-/Y mice compared to that in AT2
+/Y mice. Hence,
we suggest that AT2 receptors may not be involved in the regulation of NADPH
oxidase activity in aorta under physiological conditions.
7.3. Protein nitration as a biochemical marker of nitrosative stress
It has been demonstrated that the biological activities of NO are highly
dependent on both anabolic and catabolic-related pathways [195]. A chemical
pathway of biological importance seems to be the formation of peroxynitrite (ONOO-)
via the interaction of NO with O2-⋅, leading to reduction of NO levels and formation of
highly reactive oxidants in vivo [171, 196]. ONOO- and related species aggressively
nitrate protein tyrosine residues, leading to the chemically stable biomarker 3NT
[197]. The formation of 3NT containing proteins has been observed in some diseases
such as inflammatory disorders [198], sepsis-related organ failure [199], and renal
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transplant rejection [200]. In addition, recent studies have shown that oxidative stress
due to Ang II infusion results in an extensive tyrosine nitration of proteins in the
vascular endothelium, which correlated with the extent of endothelial dysfunction and
this was probably associated with increased production of ONOO- [201] [90]. Thus,
3NT immunoreactivity is considered to be a marker of concomitant formation of NO
and ROS and can be detected by Western blot analysis.  On the basis of these
considerations, it was of interest to examine the protein nitration, which could be
used as a biochemical marker to nitrosative stress. In addition, the relative
contribution of AT1A receptor to ONOO--induced
 nitrosative stress awaits elucidation.
Interestingly, and as an additional evidence for the decreased basal O2 -⋅
 level
in aortic tissues of AT1A
-/- mice, we found that 3NT contents were significantly
decreased in the aorta of AT1A
-/- mice compared to that in AT1A
+/+ mice. In addition,
the reduced 3NT immunoreactivity was also correlated with the decrease in Nox1
and Nox4 expression levels, demonstrating a crucial role of NADPH oxidase in AT1A
receptors-induced nitrosative and oxidative stress. In a good agreement with this
concept, Wang et al. (2002) [202] have demonstrated that the elevation of NADPH
oxidase activity and O2-⋅
 production was associated with increased 3NT
immunoreactivity in mouse aorta infused by Ang II.
7.4. Effect of the targeted deletion of AT1A or AT2 receptors on
vascular functions
The endothelium plays a key role in the local regulation of the vasomotor tone
[203]. Several studies have demonstrated the importance of endothelium-derived
factor (EDRF)/NO in both basal and stimulated control of the vascular tone [203].
Several years before EDRF was identified as NO, various group reported that O2-⋅
has limiting step on EDRF bioactivity [44, 204]. Hence, endothelium plays a crucial
role in the regulation of vascular tone by a process catalyzed by NO synthase (NOS),
NO and citrulline is formed from the substrates molecular oxygen and L-arginine. The
main receptor for NO is guanylyl cyclase, its activation by NO results in formation of
smooth muscle cGMP, which in turn contributes to vascular-relaxation. On the other
hand, Ang II induced NADPH oxidase-mediated oxidative stress is implicated in
endothelial dysfunction associated with many pathological conditions. Supporting
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this, systemic administration of subpressor dose of Ang II for 3 days was reported to
increase peroxynitrite formation and impair the endothelial function [201], further,
inhibition of AT1 receptor activation using AT1 receptor antagonists or ACE inhibitor
improved the endothelial dysfunction [205]. Similar improvements were also
observed in microvasculature [206] and in aorta isolated from rats with myocardial
infarction, pretreated with AT1 receptor antagonist [207].
Previously, Ang II was reported to increase cGMP levels, in cultured bovine
aortic endothelial cell [208, 209], via an AT2 receptor-mediated, NO (and presumably
sGC)-dependent pathway [208]. However, few reports suggest that Ang II-induced
activation of the cellular NO-cGMP pathway may be mediated partially [210], or in
some cases, exclusively by AT1 receptors [209, 211, 212]. To date, these studies
have been performed in both, cell culture and isolated vascular preparations,
suggesting that AT1 and AT2 receptors do not always act in a direct opposition to
each other, at least, at NO–cGMP pathway. On the other hand, the specific receptor
subtypes of Ang II that may contribute to NO-cGMP pathway under physiological
condition remained to be addressed. In the present study, we observed that while
eNOS and sGC subunits were downregulated in AT2
-/Y mice, they remained
unaffected in AT1A
-/- mice. Our results suggest that AT2 receptors have a direct
correlation to NO synthesis and NO-cGMP signaling, while AT1A receptors are devoid
this effect. Supporting our findings in aorta from AT2
-/Ymice, Tanaka et al. (1999)
[213] have shown that the AT2 receptor gene disruption results in a decrease in aortic
cGMP content. In contrast, transgenic mice overexpressing AT2 receptors have a
high aortic cGMP content normalized by either NO-synthesis blockade or bradykinin
B2 receptor blockade [19]. Our results are also consistent with the previous reports
demonstrating that AT2 receptors blockade abolished Ang II-induced increased
cGMP level in renal interstitial fluid of rats [214] as well as NOS inhibition [215, 216],
thereby confirming a direct link between AT2 receptor activation and subsequent
bradykinin synthesis/release. Accordingly, our study provides an interesting fact that
AT2 receptors not only regulate the NO signaling at the eNOS level but also at the
NO cyclase receptors sGa1/b1.
Recent studies have suggested that AT2 receptor might oppose actions of the
AT1 receptor with respect to blood pressure and cellular proliferation [217] under
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pathological conditions [19, 218]. To address weather such a counter-regulatory
mechanism exists under physiological conditions and functionally relevant,
endothelium-dependent and independent relaxation response in thoracic aorta from
AT1A and AT2 receptors gene targeting mice. Interestingly, the reduction in NADPH
oxidase expression or activity in aorta of AT1A
-/- mice or the downregulation of eNOS
and sGC expression levels were reflected on the increased ACh-induced endothelial-
dependent NO mediated vasorelaxation in aorta of AT1A
-/- mice and reduced
sensitivity to ACh-induced endothelium-dependent relaxation as well as the NO
donor spermine NONOate-induced endothelium-independent relaxation aorta from
AT2
-/Y mice, respectively. Thus, we suggest the downregulation of eNOS may
account for the decreased sensitivity to ACh-induced endothelium dependent
vasodilatation, whereas the decreased in sGC expression may explain the reduced
sensitivity to spermine NONOate-induced endothelium independent vasodilatation.
Our findings concerning spermine NONOate are in agreed with Schrammel et
al.(1998) [219], indicating that sGC is a major physiological target of NO-donor
compounds such as molsidomine. Although the molecular targets of NO are varied
[41], the major function of endothelial NO is to activate a sGC in underlying VSMCs,
leading to relaxation of the muscles.
Since differences observed in ACh-induced relaxation in aorta of AT1A
-/- mice were
reverted by apocynin or SOD, we suggest that basal O2-⋅, produced from NADPH
oxidase significantly counters the relaxation process. Hence, we for the first time
provide evidence to the counter-regulatory effects of AT2 and AT1A receptors on
vascular tone under physiological conditions and suggest that AT2 but not AT1A
receptors modulate the NO-cGMP pathway under physiological conditions. Thus,
reciprocal changes in Nox/GC expression were accommodated by tyrosine nitration
and apocynin-sensitive vasomotor activity.
Although we can not directly exclude the possible involvement of Nox1 and Nox2,
however the facts that Nox2 is not constitutively active [220, 221], expression of
Nox1 and Nox2 being low or negligible in vasculatures [181] and the report
suggesting that gp91phox (Nox2) is not essential for modulating vascular tone [220],
prompt us to suggest Nox4 as quantitatively the most relevant isoform for Ang II
induced O2-⋅ production under physiological conditions.  Supporting this hypothesis,
Nox2 protein expression level was not altered in the aorta of AT1A
-/- mice compared
to that in AT1A
+/+ mice Therefore, this may raise the possibility that Nox4 is
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predominantly involved in the functional consequences in aorta of AT1A
-/- mice.
Supporting this hypothesis, Sorescu et al. (2002) [83] reported that Nox4 is
abundantly expressed in cultured endothelial cells. More recently, Ago et al. (2004)
[155] demonstrated that Nox4 is the major catalytic component of NADPH oxidases
in endothelial cells. A strong correlation between p22phox / Nox4 expression and
NADPH oxidase activity, with endothelial function, in arteries from patients with
coronary heart diseases was reported [222]. Furthermore, Nox4 expression level was
markedly higher than Nox1 in aortic VSMCs [87, 101].
Concerning the functional relevance of AT2 receptor in the lung, we observed
an elevation in arterial pulmonary pressure in the lung of AT2
-/Y mice compared to
that in AT2
+/Y mice. We suggest that decreased protein expressions of sGCb1 subunit
as well as eNOS a possible explanation for this elevated arterial pulmonary pressure.
We exclude a putative role of NADPH oxidase, at least, under physiological
conditions, as we could not observe any alteration in the activity of this enzyme in
lung homogenates of AT2
-/Y mice compared to that in AT2
+/Y mice (data not shown).
Thus, we demonstrate that the protective role of AT2 receptor in the pulmonary
vessels also is mediated via NO-cGMP vasodilator cascade, confirming the recent
study from Olson et al. (2004) [223]. Accordingly, the AT2 receptor is indeed linked to
the increased eNOS expression as well as NO production in lung tissues. However,
the functional significance of AT2 receptor in the pulmonary vasculature requires
more in-depth analysis in the future.
In conclusion, these novel findings provide evidence for the molecular
regulation of NADPH oxidase isoforms (Nox1 and Nox4) in vivo by physiological Ang
II levels. Our observations support the activation of AT1A receptor being associated
with oxidative stress via Nox1 and Nox4. In addition, we suggest Nox4 to be the
predominant contributor to O2-⋅ production under physiological Ang II concentrations.
Further, this study demonstrates that the Ang II receptor subtypes (AT1A and AT2)
differentially regulate NO signaling pathways and vascular tones. While AT1A
receptor–induced Nox4 (or Nox1) expression leading to increased oxidative stress;
AT2 receptor was found to have a protective role not only by increasing eNOS, but
also via the upregulation of NO guanylyl cyclase receptors. Thus, our study while
supporting the need for specific and selective Nox4 (or Nox1) inhibitors in treating a
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broad range of cardiovascular complications, highlights the interesting facts that an
endogenous ligand (Ang II) having two distinct receptors with opposing functions
under physiological conditions, which should be borne in mind while selectively
modulating the undesirable physiology for therapeutic benefits.
Overall, these results showed that Ang II exerts countervailing mechanism on the
vasculature by AT1A receptor-dependent detrimental oxidative stress and AT2
receptor-dependent enhanced nitrinergic signaling. Both observations provide a
rational for selective interference with Ang II signaling in cardiovascular therapy.
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8. Summary
Ang II is a potent vasoconstrictor agent and elicits its physiological effects on
the vasculature via two distinct receptors AT1 and AT2. Among AT1 receptors, two
subtypes, AT1A and AT1B have been identified in rat and mouse. Recently, NADPH
oxidase has been identified as a major enzymatic source of ROS in the vasculature.
It is widely accepted that AT1 receptors are predominantly involved in
NADPH–derived ROS formation. However, there is no available information
concerning the in vivo regulation and functional significance of Nox1 and Nox4 by
Ang II under physiological conditions. Therefore, we took advantage of Ang II (AT1A
or AT2) receptors-deficient mice (AT1A
-/- and AT2
-/Y) as powerful tools to examine the
expressional regulation and functional consequences of Nox1 and Nox4 by Ang II
(AT1A and AT2) receptors under these conditions. Besides, we attempted to
investigate the functional interplay between Ang II receptors (AT1A and AT2) and NO
signalling pathway.
In the isolated aorta of mice genetically deficient in the AT1A receptor, we
observed that Nox1 and Nox4 levels were significantly downregulated versus their
respective AT1A
+/+ mice. Functionally, this was associated with attenuated 3NT
immunoreactivity (a stable biomarker of nitrosative stress) and the basal activity of
NADPH oxidase. Interestingly, this decrease in NADPH-dependent O2-⋅ production
was exclusively reflected in an increased efficacy of ACh-induced endothelium-
dependent relaxation. Importantly, the difference in maximal relaxation-induced by
ACh between AT1A
-/- and AT1A
+/+ mice was inhibited by either SOD or apocynin,
suggesting that indeed NADPH oxidase-derived O2-⋅ formation is involved. However,
Nox2 protein level remained unchanged in the aorta of AT1A
-/- and AT2
-/Y mice
compared to their respective wt.
Collectively, these findings provide in vivo evidence for Nox4 and Nox1-
induced oxidative stress as a pathophysiological mechanism of AT1A receptors-
impaired endothelium-dependent vasodilatation. Furthermore, based on the fact that
Nox4 as being quantitatively the most relevant isoform under physiological
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conditions, we suggest that this isoform may predominantly contribute to these
functional consequences.
Surprisingly, in the aorta of AT2
-/Y mice, there was neither alteration in Nox4
expression nor in NADPH oxidase-dependent O2-⋅ production compared to that in
AT2
+/Y mice. Of interest, the aorta of these mice exhibited a marked downregulation
in NO receptor cyclase subunits sGC a1/b1 and eNOS protein expression compared
that in AT2
+/Y mice.  Nevertheless, in the aorta of AT1A
-/- mice, the protein expression
of a1/b1 subunits as well as eNOS protein expression remained unchanged
compared to that in AT1A
+/+ mice. Functionally, the downregulation in NO solubale
guanylyl cyclase receptors a1/b1 as well as eNOS expression levels was reflected in
reduced sensitivity or affinity to ACh as well spermine NONOate–induced
endothelium dependent or independent vasodilatation in the aorta of AT2
-/Y mice,
respectively.
In conclusion, our data provide, an important evidence for the molecular
mechanisms of countervailing effects of AT1A (stimulatory) and AT2 (inhibitory)
receptors on vascular functions by upregulation of Nox4 (or Nox1)-mediated
oxidative stress versus the NO-sensitive guanylyl cyclase under physiological
conditions. Thus, selective AT1 receptor blockade may be clinically advantageous by
inhibiting detrimental ROS formation and simultaneously leaving the beneficial sGC
signaling untouched.
A summary of our main findings in the present study is illustrated in Fig. 8.1.
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Fig. 8.1. As shown, Ang II exerts countervaing mechanisms on the vasculature
by AT1A and AT2 receptors. Whereas AT1A receptor mediated oxidative stress
via upregulation of Nox4 (Nox1) expression, AT2 receptor is involved in the
nitrinergic signaling via increasing the expression of NO receptors soluble
guanylyl cyclase as well as eNOS.
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9. Zusammenfassung
Angiotensin II (Ang II) ist ein wichtiges vasokonstriktorisches Agens, welches
seine physiologischen Effekte über zwei verschiedene Rezeptoren vermittelt: AT1
und AT2. In Ratte und Maus sind zwei Subtypen des AT1 Rezeptors identifiziert
worden, namentlich AT1A und AT1B. Unlängst ist die NADPH Oxidase als wichtigste
enzymatische Quelle für reaktive Sauerstoffspezies (ROS) beschrieben worden.
Dieses Oxidasesystem scheint durch Ang II über die AT1 Rezeptoren aktiviert zu
werden. In der vorliegenden Studie sollte geklärt werden, welche physiologische
Bedeutung den Oxidase-Isoformen Nox1 und Nox4 bezüglich des AT1A Rezeptors
zukommt. Weiterhin wurde eine mögliche protektive Rolle von AT2 untersucht. Zu
diesem Zweck bedienten wir uns knockout Mäusen, in denen entweder das Gen für
AT1A  (AT1A
-/-) oder für AT2  (AT2
-/Y) deletiert wurde. Mit Hilfe dieser Modelle
bestimmten wir die in vivo Regulation der Nox1 und Nox4 Proteinexpression durch
AT1A bzw. AT2 Rezeptoren und deren funktionelle Signifikanz anhand von
Superoxidmessungen und Vasorelaxationstudien. Außerdem untersuchten wir die
Wechselwirkungen zwischen den Ang II Rezeptoren und dem Stickstoffmonoxid (NO)
Signalweg.
In isolierten Aorten von AT1A
-/- Mäusen fanden wir eine signifikante
Downregulation in der Nox1 und Nox4 Proteinexpression im Vergleich zu den
Wildtyp-Mäusen (AT1A
+/+). Funktionell wurde dies durch eine schwächere 3NT
Immunoreaktivität (Biomarker für nitrosativen Stress) und einer geringeren
Basalaktivität der NADPH Oxidase unterstrichen. Interessanterweise ging diese
Abnahme der NADPH abhängigen Superoxidproduktion einher mit einer erhöhten
Effizienz der Acetylcholin-induzierten, endothelabhängigen Gefäßrelaxation. Der
Unterschied in der maximalen Gefäßrelaxation zwischen AT1A
-/- und AT1A
+/+ Mäusen
konnte durch SOD und Apocynin aufgehoben werden, was auf eine Beteiligung der
NADPH Oxidase abhängigen Superoxidproduktion schliessen lässt.
Zusammengefasst weisen diese Daten daraufhin, dass der durch Nox4 (oder Nox1)
induzierte nitrosative Stress eine pathophysiologische Rationale des AT1A Rezeptors
darstellt, welche in einer beeinträchtigten Gefäßrelaxation resultieren kann. Da Nox4
die unter physiologischen Bedingungen quantitativ bedeutendere Isoform ist, denken
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wir, dass vor allem dieses Homologe für die AT1A Rezeptors vermittelte ROS-Bildung
und ihre Konsequenzen verantwortlich ist.
Überraschenderweise konnten in den Aorten von AT2
-/Y Mäusen verglichen mit den
Wildtyp-Mäusen (AT2
+/Y) weder Veränderungen bezüglich der Nox4 Expression noch
der NADPH-abhängigen Superoxidproduktion gefunden werden. Allerdings war die
Proteinexpression der löslichen Guanylatcyclase (sGCa1/b1) und der endothelialen
NO-Synthase (eNOS)in diesem Gewebe erniedrigt, im Gegensatz zu AT1A
-/-
Mäusen,bei denen kein Unterschied im Vergleich zum Wildtyp detektiert werden
konnte. Funktionell äusserte sich die Downregulation dieser NO pathway Enzyme in
einer reduzierten Relaxationsantwort auf das Acetylcholin und Spermine NONOate.
Zusammenfassend kann man sagen, dass die vorliegenden Daten einen
Einblick in die molekularen Mechanismen für die entgegengesetzten Effekte der AT1A
und AT2 Rezeptoren im vaskuläresystem geben. Unter physiologischen Bedingungen
wirkt dabei der AT1A Rezeptor stimulierend auf die vaskuläre Funktion durch
Erhöhung des Nox4 (oder Nox1) vermittelten oxidativen Stress, während der AT2
Rezeptor diese durch Hochregulation von sGC und eNOS hemmt. In diesem
Zusammenhang könnte ein selektiver AT1A Rezeptorblocker klinisch von Vorteil sein,
indem er die ROS Bildung hemmt, gleichzeitig aber den protektiven NO Signalweg
unberührt läßt. Die Zusammenfassung der wesentlichen Erkenntnisse dieser Studie
ist illustriert in Fig. 8.1.
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